{
    "info": {
        "nct_id": "NCT05558982",
        "official_title": "Phase II Trial of BXCL701 and Pembrolizumab in Patients With Metastatic Pancreatic Ductal Adenocarcinoma",
        "inclusion_criteria": "* Histologically-confirmed pancreatic ductal adenocarcinoma with metastatic disease (mixed histology is acceptable as long adenocarcinoma is the dominant histological subtype)\n* Patient must consent to two mandatory biopsies and have tumor amenable to serial core biopsies\n* Measurable disease by iRECIST v. 1.1 criteria (tumor ≥ 1 cm in longest diameter on axial image on CT or MRI and/or lymph node(s) ≥ 1.5 cm in short axis on CT or MRI) on baseline imaging\n* Documented progression of disease or intolerance on at least one regimen for metastatic disease (progression during or within 3 months of the completion of adjuvant therapy is acceptable)\n* Eastern Cooperative Oncology Group (ECOG) performance status (PS) of 0-2 (see Table 2)\n* Age ≥ 18 years\n* Subjects with no brain metastases or a history of previously treated brain metastases who have been treated by surgery or stereotactic radiosurgery (SRS) at least 4 weeks prior to enrollment and have a baseline MRI that shows no evidence of active intracranial disease\n* Patients with available standard 12-lead ECG with the following parameters at screening (defined as the mean of the triplicate ECGs):\n\n  o QTcB (Bazett's formula) interval at screening <480msec\n* Bone marrow function: absolute neutrophil count (ANC) ≥ 1,500/mm3; Platelets ≥100 × 109/L; hemoglobin ≥ 8.0 g/dL (with no prior red blood cell transfusions during the prior 14 days)\n* Renal function: serum creatinine ≤ 1.5 × upper normal limit of institution's normal range or creatinine clearance ≥ 50 mL/min/1.73 m2 for subjects with creatinine levels above institutional normal\n* Hepatic function: AST and ALT ≤ 3.0 × the upper normal limit of institution's normal range. Total bilirubin ≤ 1.5 × the upper normal limit of institution's normal range. For subjects with liver metastases, AST and ALT < 5 × the upper normal limit of institution's normal range, and total bilirubin >1.5 - 3.0 x the upper normal limit of institution's normal range are acceptable as long as there is no persistent nausea, vomiting, right upper quadrant pain or tenderness, fever, rash, or eosinophilia.\n* Patients must have fully recovered from all effects of surgery. Patients must have had at least two weeks after minor surgery and four weeks after major surgery before starting therapy. Minor procedures requiring \"Twilight\" sedation such as endoscopies or mediport placement may only require a 24-hour waiting period, but this must be discussed with an investigator.\n* Women of childbearing potential must have a negative serum pregnancy test during the screening period and on C1D1 and/or postmenopausal women must be amenorrheic for at least 12 months to be considered of non-childbearing potential\n* Patient is capable of swallowing pills whole.\n* Patient is capable of understanding and complying with parameters as outlined in the protocol and able to sign and date the informed consent, approved by the Institutional Review Board (IRB), prior to the initiation of any screening or study-specific procedures.\n* Patient's acute toxic effects of previous anticancer therapy have resolved to ≤ Grade 1 except for Grade 2-3 peripheral neuropathy or any grade of alopecia.\n* Male patients and their female partners of childbearing potential must agree and commit to use a barrier contraception (e.g., condom with spermicidal foam/gel/film/cream/ suppository) throughout the duration of the study until at least 6 months following the last dose of study drug, in addition to their female partners using either an intrauterine device or hormonal contraception and continuing until at least 6 months following the last dose of study drug. This criterion may be waived for male patients who have had a vasectomy >6 months before signing the informed consent form.\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
        "exclusion_criteria": "* Patients previously exposed to FAP inhibitors, DPP inhibitors, or monoclonal antibodies targeting anti-PD-1, anti-PD-L1, or anti-CTLA-4.\n* Prior anti-tumor therapy within 2 weeks of C1D1 (defined as, but not limited to, anti-cancer agents (cytotoxic chemotherapy, immunotherapy, and biologic therapy), radiotherapy, and investigational agents), the \"washout period.\"\n* Patient has any other concurrent severe and/or uncontrolled medical condition that would, in the investigator's judgment, cause unacceptable safety risks, contraindicate patient participation in the clinical study or compromise compliance with the protocol (e.g. chronic symptomatic pancreatitis, chronic active hepatitis, active untreated or uncontrolled fungal, bacterial, or viral infection).\n* Women who are pregnant or breastfeeding.\n* Psychiatric illness or social situation that would limit compliance with study requirements.\n* Concurrent malignancy or malignancy within 2 years prior to C1D1, with the exception of adequately treated cutaneous basal or squamous cell carcinoma, non-melanomatous skin cancer, curatively resected cervical cancer, or any locally treated malignancy deemed low likelihood for recurrence or metastasis by the investigator.\n* Patients with central nervous system (CNS) involvement unless they meet ALL of the following criteria:\n\n  * At least 4 weeks from prior therapy completion (including radiation and/or surgery) to starting the study treatment\n  * Clinically stable CNS tumor at the time of screening and not receiving steroids and/or enzyme-inducing anti-epileptic medications for brain metastases.\n* Patient has impairment of gastrointestinal (GI) function or GI disease that may significantly alter the absorption of the study drugs (e.g., ulcerative diseases, uncontrolled nausea, vomiting, diarrhea, malabsorption syndrome, or small bowel resection).\n* Patient has a known history of HIV infection or chronic, active hepatitis B or C (testing is not mandatory) - patients with hepatitis C status-post treatment with undetectable viral load are eligible.\n* Patient has any other concurrent severe and/or uncontrolled medical condition that would, in the investigator's judgment, cause unacceptable safety risks, contraindicate patient participation in the clinical study or compromise compliance with the protocol (e.g. chronic pancreatitis, chronic active hepatitis, active untreated or uncontrolled fungal, bacterial or viral infections, etc.).\n* Patient has uncontrolled, clinically significant pulmonary disease (e.g. chronic obstructive pulmonary disease, pulmonary hypertension) that in the opinion of the investigator would put the patient at significant risk for pulmonary complications during the study.\n* Clinically significant, uncontrolled heart disease and/or cardiac repolarization abnormalities, including any of the following:\n\n  * History of acute coronary syndromes (including myocardial infarction, unstable angina, coronary artery bypass grafting, coronary angioplasty, or stenting) or symptomatic pericarditis within 6 months prior to screening\n  * History of documented congestive heart failure (New York Heart Association functional classification III-IV)\n  * Documented cardiomyopathy\n  * Left Ventricular Ejection Fraction (LVEF) <50% as determined by Multiple Gated acquisition (MUGA) scan or echocardiogram (ECHO) at screening\n  * Clinically significant cardiac arrhythmias (e.g. ventricular tachycardia), complete left bundle branch block, high-grade AV block (e.g. bifascicular block, Mobitz type II and third-degree AV block)\n  * Long QT syndrome or family history of idiopathic sudden death or congenital long QT syndrome, or any of the following:\n  * Risk factors for Torsades de Pointe (TdP) including uncorrected hypokalemia or hypomagnesemia, history of cardiac failure, or history of clinically significant/symptomatic bradycardia.\n  * Concomitant use of medication(s) with a known risk to prolong the QT interval and/or known to cause Torsades de Pointe that cannot be discontinued (within 5 half-lives or 7 days prior to starting study drug) or replaced by safe alternative medication\n  * Inability to determine the QT interval on screening\n* Patients with history of symptomatic orthostatic hypotension within 3 months prior to enrollment, defined as a drop in systolic blood pressure (SBP) of ≥ 20 mmHg or diastolic blood pressure (DBP) of ≥ 10 mmHg with assumption of an upright posture.\n* Patients with a history of (non-infectious) pneumonitis that required steroids, current pneumonitis, or those who have a history of interstitial lung disease.\n* Patients who have received a live-virus vaccination within 30 days of planned treatment start date.\n* Patient must not have active known or suspected autoimmune disease requiring systemic treatment in the past 2 years (i.e., with use of disease modifying agents, corticosteroids, or immunosuppressive drugs). Subjects with type I diabetes mellitus, hypothyroidism only requiring hormone replacement, skin disorders (such as vitiligo, psoriasis, or alopecia) not requiring systemic treatment, or conditions not expected to recur in the absence of an external trigger (e.g., celiac disease) are permitted to enroll.\n* Patient must not have a condition requiring systemic treatment with either corticosteroids or other immunosuppressive medications within 14 days of randomization. Inhaled or topical steroids, and adrenal replacement steroid doses ≤10 mg daily prednisone equivalents are permitted in the absence of active autoimmune disease.\n* Prisoners.",
        "miscellaneous_criteria": ""
    },
    "inclusion_lines": [
        {
            "identified_line": {
                "line": "* Patient is capable of swallowing pills whole.",
                "criterions": [
                    {
                        "exact_snippets": "Patient is capable of swallowing pills whole",
                        "criterion": "ability to swallow pills whole",
                        "requirement": {
                            "requirement_type": "capability",
                            "expected_value": true
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "Patient is capable of swallowing pills whole",
                        "criterion": "ability to swallow pills whole",
                        "requirement": {
                            "requirement_type": "capability",
                            "expected_value": true
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "Healthy volunteers allowed",
                "criterions": [
                    {
                        "exact_snippets": "Healthy volunteers allowed",
                        "criterion": "healthy volunteer status",
                        "requirement": {
                            "requirement_type": "eligibility",
                            "expected_value": true
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "Healthy volunteers allowed",
                        "criterion": "healthy volunteer status",
                        "requirement": {
                            "requirement_type": "eligibility",
                            "expected_value": true
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "* Histologically-confirmed pancreatic ductal adenocarcinoma with metastatic disease (mixed histology is acceptable as long adenocarcinoma is the dominant histological subtype)",
                "criterions": [
                    {
                        "exact_snippets": "Histologically-confirmed pancreatic ductal adenocarcinoma",
                        "criterion": "pancreatic ductal adenocarcinoma",
                        "requirement": {
                            "requirement_type": "confirmation method",
                            "expected_value": "histologically-confirmed"
                        }
                    },
                    {
                        "exact_snippets": "metastatic disease",
                        "criterion": "metastatic disease",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "mixed histology is acceptable as long adenocarcinoma is the dominant histological subtype",
                        "criterion": "adenocarcinoma as dominant histological subtype",
                        "requirement": {
                            "requirement_type": "dominance",
                            "expected_value": "adenocarcinoma"
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "Histologically-confirmed pancreatic ductal adenocarcinoma",
                        "criterion": "pancreatic ductal adenocarcinoma",
                        "requirement": {
                            "requirement_type": "confirmation method",
                            "expected_value": "histologically-confirmed"
                        }
                    },
                    {
                        "exact_snippets": "metastatic disease",
                        "criterion": "metastatic disease",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "mixed histology is acceptable as long adenocarcinoma is the dominant histological subtype",
                        "criterion": "adenocarcinoma as dominant histological subtype",
                        "requirement": {
                            "requirement_type": "dominance",
                            "expected_value": "adenocarcinoma"
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "* Patients must have fully recovered from all effects of surgery. Patients must have had at least two weeks after minor surgery and four weeks after major surgery before starting therapy. Minor procedures requiring \"Twilight\" sedation such as endoscopies or mediport placement may only require a 24-hour waiting period, but this must be discussed with an investigator.",
                "criterions": [
                    {
                        "exact_snippets": "Patients must have fully recovered from all effects of surgery",
                        "criterion": "recovery from surgery",
                        "requirement": {
                            "requirement_type": "recovery_status",
                            "expected_value": "fully recovered"
                        }
                    },
                    {
                        "exact_snippets": "Patients must have had at least two weeks after minor surgery ... before starting therapy",
                        "criterion": "time since minor surgery",
                        "requirement": {
                            "requirement_type": "minimum_time_since_surgery",
                            "expected_value": {
                                "operator": ">=",
                                "value": 2,
                                "unit": "weeks"
                            }
                        }
                    },
                    {
                        "exact_snippets": "four weeks after major surgery before starting therapy",
                        "criterion": "time since major surgery",
                        "requirement": {
                            "requirement_type": "minimum_time_since_surgery",
                            "expected_value": {
                                "operator": ">=",
                                "value": 4,
                                "unit": "weeks"
                            }
                        }
                    },
                    {
                        "exact_snippets": "Minor procedures requiring \"Twilight\" sedation such as endoscopies or mediport placement may only require a 24-hour waiting period, but this must be discussed with an investigator",
                        "criterion": "time since minor procedure with 'Twilight' sedation",
                        "requirement": {
                            "requirement_type": "minimum_time_since_procedure",
                            "expected_value": {
                                "operator": ">=",
                                "value": 24,
                                "unit": "hours"
                            }
                        }
                    },
                    {
                        "exact_snippets": "Minor procedures requiring \"Twilight\" sedation such as endoscopies or mediport placement may only require a 24-hour waiting period, but this must be discussed with an investigator",
                        "criterion": "time since minor procedure with 'Twilight' sedation",
                        "requirement": {
                            "requirement_type": "investigator_approval",
                            "expected_value": true
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "Patients must have fully recovered from all effects of surgery",
                        "criterion": "recovery from surgery",
                        "requirement": {
                            "requirement_type": "recovery_status",
                            "expected_value": "fully recovered"
                        }
                    },
                    {
                        "or_criteria": [
                            {
                                "and_criteria": [
                                    {
                                        "exact_snippets": "Patients must have had at least two weeks after minor surgery ... before starting therapy",
                                        "criterion": "time since minor surgery",
                                        "requirement": {
                                            "requirement_type": "minimum_time_since_surgery",
                                            "expected_value": {
                                                "operator": ">=",
                                                "value": 2,
                                                "unit": "weeks"
                                            }
                                        }
                                    }
                                ]
                            },
                            {
                                "and_criteria": [
                                    {
                                        "exact_snippets": "four weeks after major surgery before starting therapy",
                                        "criterion": "time since major surgery",
                                        "requirement": {
                                            "requirement_type": "minimum_time_since_surgery",
                                            "expected_value": {
                                                "operator": ">=",
                                                "value": 4,
                                                "unit": "weeks"
                                            }
                                        }
                                    }
                                ]
                            },
                            {
                                "and_criteria": [
                                    {
                                        "exact_snippets": "Minor procedures requiring \"Twilight\" sedation such as endoscopies or mediport placement may only require a 24-hour waiting period, but this must be discussed with an investigator",
                                        "criterion": "time since minor procedure with 'Twilight' sedation",
                                        "requirement": {
                                            "requirement_type": "minimum_time_since_procedure",
                                            "expected_value": {
                                                "operator": ">=",
                                                "value": 24,
                                                "unit": "hours"
                                            }
                                        }
                                    },
                                    {
                                        "exact_snippets": "Minor procedures requiring \"Twilight\" sedation such as endoscopies or mediport placement may only require a 24-hour waiting period, but this must be discussed with an investigator",
                                        "criterion": "time since minor procedure with 'Twilight' sedation",
                                        "requirement": {
                                            "requirement_type": "investigator_approval",
                                            "expected_value": true
                                        }
                                    }
                                ]
                            }
                        ]
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "* Patient is capable of understanding and complying with parameters as outlined in the protocol and able to sign and date the informed consent, approved by the Institutional Review Board (IRB), prior to the initiation of any screening or study-specific procedures.",
                "criterions": [
                    {
                        "exact_snippets": "Patient is capable of understanding and complying with parameters as outlined in the protocol",
                        "criterion": "ability to understand and comply with protocol parameters",
                        "requirement": {
                            "requirement_type": "capability",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "able to sign and date the informed consent, approved by the Institutional Review Board (IRB), prior to the initiation of any screening or study-specific procedures",
                        "criterion": "ability to provide informed consent",
                        "requirement": {
                            "requirement_type": "capability",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "able to sign and date the informed consent, approved by the Institutional Review Board (IRB), prior to the initiation of any screening or study-specific procedures",
                        "criterion": "ability to provide informed consent",
                        "requirement": {
                            "requirement_type": "timing",
                            "expected_value": "prior to the initiation of any screening or study-specific procedures"
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "Patient is capable of understanding and complying with parameters as outlined in the protocol",
                        "criterion": "ability to understand and comply with protocol parameters",
                        "requirement": {
                            "requirement_type": "capability",
                            "expected_value": true
                        }
                    },
                    {
                        "and_criteria": [
                            {
                                "exact_snippets": "able to sign and date the informed consent, approved by the Institutional Review Board (IRB), prior to the initiation of any screening or study-specific procedures",
                                "criterion": "ability to provide informed consent",
                                "requirement": {
                                    "requirement_type": "capability",
                                    "expected_value": true
                                }
                            },
                            {
                                "exact_snippets": "able to sign and date the informed consent, approved by the Institutional Review Board (IRB), prior to the initiation of any screening or study-specific procedures",
                                "criterion": "ability to provide informed consent",
                                "requirement": {
                                    "requirement_type": "timing",
                                    "expected_value": "prior to the initiation of any screening or study-specific procedures"
                                }
                            }
                        ]
                    },
                    {
                        "and_criteria": []
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "* Patients with available standard 12-lead ECG with the following parameters at screening (defined as the mean of the triplicate ECGs):",
                "criterions": [
                    {
                        "exact_snippets": "Patients with available standard 12-lead ECG",
                        "criterion": "standard 12-lead ECG",
                        "requirement": {
                            "requirement_type": "availability",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "parameters at screening (defined as the mean of the triplicate ECGs)",
                        "criterion": "ECG parameters at screening",
                        "requirement": {
                            "requirement_type": "measurement method",
                            "expected_value": "mean of the triplicate ECGs"
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "Patients with available standard 12-lead ECG",
                        "criterion": "standard 12-lead ECG",
                        "requirement": {
                            "requirement_type": "availability",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "parameters at screening (defined as the mean of the triplicate ECGs)",
                        "criterion": "ECG parameters at screening",
                        "requirement": {
                            "requirement_type": "measurement method",
                            "expected_value": "mean of the triplicate ECGs"
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "* Hepatic function: AST and ALT ≤ 3.0 × the upper normal limit of institution's normal range. Total bilirubin ≤ 1.5 × the upper normal limit of institution's normal range. For subjects with liver metastases, AST and ALT < 5 × the upper normal limit of institution's normal range, and total bilirubin >1.5 - 3.0 x the upper normal limit of institution's normal range are acceptable as long as there is no persistent nausea, vomiting, right upper quadrant pain or tenderness, fever, rash, or eosinophilia.",
                "criterions": [
                    {
                        "exact_snippets": "AST and ALT ≤ 3.0 × the upper normal limit of institution's normal range",
                        "criterion": "AST",
                        "requirement": {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<=",
                                "value": 3.0,
                                "unit": "x upper normal limit"
                            }
                        }
                    },
                    {
                        "exact_snippets": "AST and ALT ≤ 3.0 × the upper normal limit of institution's normal range",
                        "criterion": "ALT",
                        "requirement": {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<=",
                                "value": 3.0,
                                "unit": "x upper normal limit"
                            }
                        }
                    },
                    {
                        "exact_snippets": "Total bilirubin ≤ 1.5 × the upper normal limit of institution's normal range",
                        "criterion": "total bilirubin",
                        "requirement": {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<=",
                                "value": 1.5,
                                "unit": "x upper normal limit"
                            }
                        }
                    },
                    {
                        "exact_snippets": "For subjects with liver metastases, AST and ALT < 5 × the upper normal limit of institution's normal range",
                        "criterion": "AST (subjects with liver metastases)",
                        "requirement": {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<",
                                "value": 5.0,
                                "unit": "x upper normal limit"
                            }
                        }
                    },
                    {
                        "exact_snippets": "For subjects with liver metastases, AST and ALT < 5 × the upper normal limit of institution's normal range",
                        "criterion": "ALT (subjects with liver metastases)",
                        "requirement": {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<",
                                "value": 5.0,
                                "unit": "x upper normal limit"
                            }
                        }
                    },
                    {
                        "exact_snippets": "total bilirubin >1.5 - 3.0 x the upper normal limit of institution's normal range are acceptable",
                        "criterion": "total bilirubin (subjects with liver metastases)",
                        "requirement": {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": ">",
                                        "value": 1.5,
                                        "unit": "x upper normal limit"
                                    },
                                    {
                                        "operator": "<=",
                                        "value": 3.0,
                                        "unit": "x upper normal limit"
                                    }
                                ]
                            }
                        }
                    },
                    {
                        "exact_snippets": "as long as there is no persistent nausea, vomiting, right upper quadrant pain or tenderness, fever, rash, or eosinophilia",
                        "criterion": "persistent nausea",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": false
                        }
                    },
                    {
                        "exact_snippets": "as long as there is no persistent nausea, vomiting, right upper quadrant pain or tenderness, fever, rash, or eosinophilia",
                        "criterion": "vomiting",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": false
                        }
                    },
                    {
                        "exact_snippets": "as long as there is no persistent nausea, vomiting, right upper quadrant pain or tenderness, fever, rash, or eosinophilia",
                        "criterion": "right upper quadrant pain or tenderness",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": false
                        }
                    },
                    {
                        "exact_snippets": "as long as there is no persistent nausea, vomiting, right upper quadrant pain or tenderness, fever, rash, or eosinophilia",
                        "criterion": "fever",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": false
                        }
                    },
                    {
                        "exact_snippets": "as long as there is no persistent nausea, vomiting, right upper quadrant pain or tenderness, fever, rash, or eosinophilia",
                        "criterion": "rash",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": false
                        }
                    },
                    {
                        "exact_snippets": "as long as there is no persistent nausea, vomiting, right upper quadrant pain or tenderness, fever, rash, or eosinophilia",
                        "criterion": "eosinophilia",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": false
                        }
                    }
                ]
            },
            "logical_structure": {
                "or_criteria": [
                    {
                        "and_criteria": [
                            {
                                "exact_snippets": "AST and ALT ≤ 3.0 × the upper normal limit of institution's normal range",
                                "criterion": "AST",
                                "requirement": {
                                    "requirement_type": "quantity",
                                    "expected_value": {
                                        "operator": "<=",
                                        "value": 3.0,
                                        "unit": "x upper normal limit"
                                    }
                                }
                            },
                            {
                                "exact_snippets": "AST and ALT ≤ 3.0 × the upper normal limit of institution's normal range",
                                "criterion": "ALT",
                                "requirement": {
                                    "requirement_type": "quantity",
                                    "expected_value": {
                                        "operator": "<=",
                                        "value": 3.0,
                                        "unit": "x upper normal limit"
                                    }
                                }
                            },
                            {
                                "exact_snippets": "Total bilirubin ≤ 1.5 × the upper normal limit of institution's normal range",
                                "criterion": "total bilirubin",
                                "requirement": {
                                    "requirement_type": "quantity",
                                    "expected_value": {
                                        "operator": "<=",
                                        "value": 1.5,
                                        "unit": "x upper normal limit"
                                    }
                                }
                            }
                        ]
                    },
                    {
                        "and_criteria": [
                            {
                                "exact_snippets": "For subjects with liver metastases, AST and ALT < 5 × the upper normal limit of institution's normal range",
                                "criterion": "AST (subjects with liver metastases)",
                                "requirement": {
                                    "requirement_type": "quantity",
                                    "expected_value": {
                                        "operator": "<",
                                        "value": 5.0,
                                        "unit": "x upper normal limit"
                                    }
                                }
                            },
                            {
                                "exact_snippets": "For subjects with liver metastases, AST and ALT < 5 × the upper normal limit of institution's normal range",
                                "criterion": "ALT (subjects with liver metastases)",
                                "requirement": {
                                    "requirement_type": "quantity",
                                    "expected_value": {
                                        "operator": "<",
                                        "value": 5.0,
                                        "unit": "x upper normal limit"
                                    }
                                }
                            },
                            {
                                "exact_snippets": "total bilirubin >1.5 - 3.0 x the upper normal limit of institution's normal range are acceptable",
                                "criterion": "total bilirubin (subjects with liver metastases)",
                                "requirement": {
                                    "requirement_type": "quantity",
                                    "expected_value": {
                                        "comparisons": [
                                            {
                                                "operator": ">",
                                                "value": 1.5,
                                                "unit": "x upper normal limit"
                                            },
                                            {
                                                "operator": "<=",
                                                "value": 3.0,
                                                "unit": "x upper normal limit"
                                            }
                                        ]
                                    }
                                }
                            },
                            {
                                "exact_snippets": "as long as there is no persistent nausea, vomiting, right upper quadrant pain or tenderness, fever, rash, or eosinophilia",
                                "criterion": "persistent nausea",
                                "requirement": {
                                    "requirement_type": "presence",
                                    "expected_value": false
                                }
                            },
                            {
                                "exact_snippets": "as long as there is no persistent nausea, vomiting, right upper quadrant pain or tenderness, fever, rash, or eosinophilia",
                                "criterion": "vomiting",
                                "requirement": {
                                    "requirement_type": "presence",
                                    "expected_value": false
                                }
                            },
                            {
                                "exact_snippets": "as long as there is no persistent nausea, vomiting, right upper quadrant pain or tenderness, fever, rash, or eosinophilia",
                                "criterion": "right upper quadrant pain or tenderness",
                                "requirement": {
                                    "requirement_type": "presence",
                                    "expected_value": false
                                }
                            },
                            {
                                "exact_snippets": "as long as there is no persistent nausea, vomiting, right upper quadrant pain or tenderness, fever, rash, or eosinophilia",
                                "criterion": "fever",
                                "requirement": {
                                    "requirement_type": "presence",
                                    "expected_value": false
                                }
                            },
                            {
                                "exact_snippets": "as long as there is no persistent nausea, vomiting, right upper quadrant pain or tenderness, fever, rash, or eosinophilia",
                                "criterion": "rash",
                                "requirement": {
                                    "requirement_type": "presence",
                                    "expected_value": false
                                }
                            },
                            {
                                "exact_snippets": "as long as there is no persistent nausea, vomiting, right upper quadrant pain or tenderness, fever, rash, or eosinophilia",
                                "criterion": "eosinophilia",
                                "requirement": {
                                    "requirement_type": "presence",
                                    "expected_value": false
                                }
                            }
                        ]
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "o QTcB (Bazett's formula) interval at screening <480msec",
                "criterions": [
                    {
                        "exact_snippets": "QTcB (Bazett's formula) interval at screening <480msec",
                        "criterion": "QTcB interval",
                        "requirement": {
                            "requirement_type": "value at screening",
                            "expected_value": {
                                "operator": "<",
                                "value": 480,
                                "unit": "msec"
                            }
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "QTcB (Bazett's formula) interval at screening <480msec",
                        "criterion": "QTcB interval",
                        "requirement": {
                            "requirement_type": "value at screening",
                            "expected_value": {
                                "operator": "<",
                                "value": 480,
                                "unit": "msec"
                            }
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "* Documented progression of disease or intolerance on at least one regimen for metastatic disease (progression during or within 3 months of the completion of adjuvant therapy is acceptable)",
                "criterions": [
                    {
                        "exact_snippets": "Documented progression of disease or intolerance on at least one regimen for metastatic disease",
                        "criterion": "progression of disease or intolerance to therapy",
                        "requirement": {
                            "requirement_type": "documentation",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "Documented progression of disease or intolerance on at least one regimen for metastatic disease",
                        "criterion": "progression of disease or intolerance to therapy",
                        "requirement": {
                            "requirement_type": "number of regimens for metastatic disease",
                            "expected_value": {
                                "operator": ">=",
                                "value": 1,
                                "unit": "regimen"
                            }
                        }
                    },
                    {
                        "exact_snippets": "Documented progression of disease or intolerance on at least one regimen for metastatic disease",
                        "criterion": "progression of disease or intolerance to therapy",
                        "requirement": {
                            "requirement_type": "setting",
                            "expected_value": "metastatic disease"
                        }
                    },
                    {
                        "exact_snippets": "progression during or within 3 months of the completion of adjuvant therapy is acceptable",
                        "criterion": "progression of disease after adjuvant therapy",
                        "requirement": {
                            "requirement_type": "timing after adjuvant therapy",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": "<=",
                                        "value": 3,
                                        "unit": "months"
                                    }
                                ]
                            }
                        }
                    }
                ]
            },
            "logical_structure": {
                "or_criteria": [
                    {
                        "and_criteria": [
                            {
                                "exact_snippets": "Documented progression of disease or intolerance on at least one regimen for metastatic disease",
                                "criterion": "progression of disease or intolerance to therapy",
                                "requirement": {
                                    "requirement_type": "documentation",
                                    "expected_value": true
                                }
                            },
                            {
                                "exact_snippets": "Documented progression of disease or intolerance on at least one regimen for metastatic disease",
                                "criterion": "progression of disease or intolerance to therapy",
                                "requirement": {
                                    "requirement_type": "number of regimens for metastatic disease",
                                    "expected_value": {
                                        "operator": ">=",
                                        "value": 1,
                                        "unit": "regimen"
                                    }
                                }
                            },
                            {
                                "exact_snippets": "Documented progression of disease or intolerance on at least one regimen for metastatic disease",
                                "criterion": "progression of disease or intolerance to therapy",
                                "requirement": {
                                    "requirement_type": "setting",
                                    "expected_value": "metastatic disease"
                                }
                            }
                        ]
                    },
                    {
                        "exact_snippets": "progression during or within 3 months of the completion of adjuvant therapy is acceptable",
                        "criterion": "progression of disease after adjuvant therapy",
                        "requirement": {
                            "requirement_type": "timing after adjuvant therapy",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": "<=",
                                        "value": 3,
                                        "unit": "months"
                                    }
                                ]
                            }
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "* Eastern Cooperative Oncology Group (ECOG) performance status (PS) of 0-2 (see Table 2)",
                "criterions": [
                    {
                        "exact_snippets": "Eastern Cooperative Oncology Group (ECOG) performance status (PS) of 0-2",
                        "criterion": "ECOG performance status",
                        "requirement": {
                            "requirement_type": "value",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": ">=",
                                        "value": 0,
                                        "unit": "N/A"
                                    },
                                    {
                                        "operator": "<=",
                                        "value": 2,
                                        "unit": "N/A"
                                    }
                                ]
                            }
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "Eastern Cooperative Oncology Group (ECOG) performance status (PS) of 0-2",
                        "criterion": "ECOG performance status",
                        "requirement": {
                            "requirement_type": "value",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": ">=",
                                        "value": 0,
                                        "unit": "N/A"
                                    },
                                    {
                                        "operator": "<=",
                                        "value": 2,
                                        "unit": "N/A"
                                    }
                                ]
                            }
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "* Patient must consent to two mandatory biopsies and have tumor amenable to serial core biopsies",
                "criterions": [
                    {
                        "exact_snippets": "Patient must consent to two mandatory biopsies",
                        "criterion": "biopsy consent",
                        "requirement": {
                            "requirement_type": "consent",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "Patient must consent to two mandatory biopsies",
                        "criterion": "biopsy consent",
                        "requirement": {
                            "requirement_type": "number of biopsies",
                            "expected_value": {
                                "operator": "=",
                                "value": 2,
                                "unit": "N/A"
                            }
                        }
                    },
                    {
                        "exact_snippets": "Patient must consent to two mandatory biopsies",
                        "criterion": "biopsy consent",
                        "requirement": {
                            "requirement_type": "mandatory",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "tumor amenable to serial core biopsies",
                        "criterion": "tumor amenability to serial core biopsies",
                        "requirement": {
                            "requirement_type": "amenability",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "tumor amenable to serial core biopsies",
                        "criterion": "tumor amenability to serial core biopsies",
                        "requirement": {
                            "requirement_type": "biopsy type",
                            "expected_value": "serial core"
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "and_criteria": [
                            {
                                "exact_snippets": "Patient must consent to two mandatory biopsies",
                                "criterion": "biopsy consent",
                                "requirement": {
                                    "requirement_type": "consent",
                                    "expected_value": true
                                }
                            },
                            {
                                "exact_snippets": "Patient must consent to two mandatory biopsies",
                                "criterion": "biopsy consent",
                                "requirement": {
                                    "requirement_type": "number of biopsies",
                                    "expected_value": {
                                        "operator": "=",
                                        "value": 2,
                                        "unit": "N/A"
                                    }
                                }
                            },
                            {
                                "exact_snippets": "Patient must consent to two mandatory biopsies",
                                "criterion": "biopsy consent",
                                "requirement": {
                                    "requirement_type": "mandatory",
                                    "expected_value": true
                                }
                            }
                        ]
                    },
                    {
                        "and_criteria": [
                            {
                                "exact_snippets": "tumor amenable to serial core biopsies",
                                "criterion": "tumor amenability to serial core biopsies",
                                "requirement": {
                                    "requirement_type": "amenability",
                                    "expected_value": true
                                }
                            },
                            {
                                "exact_snippets": "tumor amenable to serial core biopsies",
                                "criterion": "tumor amenability to serial core biopsies",
                                "requirement": {
                                    "requirement_type": "biopsy type",
                                    "expected_value": "serial core"
                                }
                            }
                        ]
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "Must have minimum age of 18 Years",
                "criterions": [
                    {
                        "exact_snippets": "minimum age of 18 Years",
                        "criterion": "age",
                        "requirement": {
                            "requirement_type": "minimum value",
                            "expected_value": {
                                "operator": ">=",
                                "value": 18,
                                "unit": "years"
                            }
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "minimum age of 18 Years",
                        "criterion": "age",
                        "requirement": {
                            "requirement_type": "minimum value",
                            "expected_value": {
                                "operator": ">=",
                                "value": 18,
                                "unit": "years"
                            }
                        }
                    }
                ]
            }
        }
    ],
    "exclusion_lines": [
        {
            "identified_line": {
                "line": "* Documented cardiomyopathy",
                "criterions": [
                    {
                        "exact_snippets": "Documented cardiomyopathy",
                        "criterion": "cardiomyopathy",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "Documented cardiomyopathy",
                        "criterion": "cardiomyopathy",
                        "requirement": {
                            "requirement_type": "documentation",
                            "expected_value": true
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "Documented cardiomyopathy",
                        "criterion": "cardiomyopathy",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "Documented cardiomyopathy",
                        "criterion": "cardiomyopathy",
                        "requirement": {
                            "requirement_type": "documentation",
                            "expected_value": true
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "* Psychiatric illness or social situation that would limit compliance with study requirements.",
                "criterions": [
                    {
                        "exact_snippets": "Psychiatric illness ... that would limit compliance with study requirements",
                        "criterion": "psychiatric illness",
                        "requirement": {
                            "requirement_type": "impact on compliance",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "social situation that would limit compliance with study requirements",
                        "criterion": "social situation",
                        "requirement": {
                            "requirement_type": "impact on compliance",
                            "expected_value": true
                        }
                    }
                ]
            },
            "logical_structure": {
                "or_criteria": [
                    {
                        "exact_snippets": "Psychiatric illness ... that would limit compliance with study requirements",
                        "criterion": "psychiatric illness",
                        "requirement": {
                            "requirement_type": "impact on compliance",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "social situation that would limit compliance with study requirements",
                        "criterion": "social situation",
                        "requirement": {
                            "requirement_type": "impact on compliance",
                            "expected_value": true
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "* Patients with central nervous system (CNS) involvement unless they meet ALL of the following criteria:",
                "criterions": [
                    {
                        "exact_snippets": "central nervous system (CNS) involvement",
                        "criterion": "central nervous system (CNS) involvement",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    }
                ]
            },
            "logical_structure": {
                "not_criteria": {
                    "exact_snippets": "central nervous system (CNS) involvement",
                    "criterion": "central nervous system (CNS) involvement",
                    "requirement": {
                        "requirement_type": "presence",
                        "expected_value": true
                    }
                }
            }
        },
        {
            "identified_line": {
                "line": "* Prisoners.",
                "criterions": [
                    {
                        "exact_snippets": "Prisoners.",
                        "criterion": "prisoner status",
                        "requirement": {
                            "requirement_type": "status",
                            "expected_value": "prisoner"
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "Prisoners.",
                        "criterion": "prisoner status",
                        "requirement": {
                            "requirement_type": "status",
                            "expected_value": "prisoner"
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "* Patient has uncontrolled, clinically significant pulmonary disease (e.g. chronic obstructive pulmonary disease, pulmonary hypertension) that in the opinion of the investigator would put the patient at significant risk for pulmonary complications during the study.",
                "criterions": [
                    {
                        "exact_snippets": "uncontrolled, clinically significant pulmonary disease (e.g. chronic obstructive pulmonary disease, pulmonary hypertension)",
                        "criterion": "pulmonary disease",
                        "requirement": {
                            "requirement_type": "control status",
                            "expected_value": "uncontrolled"
                        }
                    },
                    {
                        "exact_snippets": "uncontrolled, clinically significant pulmonary disease (e.g. chronic obstructive pulmonary disease, pulmonary hypertension)",
                        "criterion": "pulmonary disease",
                        "requirement": {
                            "requirement_type": "clinical significance",
                            "expected_value": true
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "uncontrolled, clinically significant pulmonary disease (e.g. chronic obstructive pulmonary disease, pulmonary hypertension)",
                        "criterion": "pulmonary disease",
                        "requirement": {
                            "requirement_type": "control status",
                            "expected_value": "uncontrolled"
                        }
                    },
                    {
                        "exact_snippets": "uncontrolled, clinically significant pulmonary disease (e.g. chronic obstructive pulmonary disease, pulmonary hypertension)",
                        "criterion": "pulmonary disease",
                        "requirement": {
                            "requirement_type": "clinical significance",
                            "expected_value": true
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "* At least 4 weeks from prior therapy completion (including radiation and/or surgery) to starting the study treatment",
                "criterions": [
                    {
                        "exact_snippets": "At least 4 weeks from prior therapy completion (including radiation and/or surgery) to starting the study treatment",
                        "criterion": "time interval from prior therapy completion to study treatment start",
                        "requirement": {
                            "requirement_type": "duration",
                            "expected_value": {
                                "operator": ">=",
                                "value": 4,
                                "unit": "weeks"
                            }
                        }
                    }
                ]
            },
            "logical_structure": {
                "not_criteria": {
                    "exact_snippets": "At least 4 weeks from prior therapy completion (including radiation and/or surgery) to starting the study treatment",
                    "criterion": "time interval from prior therapy completion to study treatment start",
                    "requirement": {
                        "requirement_type": "duration",
                        "expected_value": {
                            "operator": ">=",
                            "value": 4,
                            "unit": "weeks"
                        }
                    }
                }
            }
        },
        {
            "identified_line": {
                "line": "* Inability to determine the QT interval on screening",
                "criterions": [
                    {
                        "exact_snippets": "Inability to determine the QT interval on screening",
                        "criterion": "QT interval determination",
                        "requirement": {
                            "requirement_type": "determinability",
                            "expected_value": true
                        }
                    }
                ]
            },
            "logical_structure": {
                "not_criteria": {
                    "exact_snippets": "Inability to determine the QT interval on screening",
                    "criterion": "QT interval determination",
                    "requirement": {
                        "requirement_type": "determinability",
                        "expected_value": true
                    }
                }
            }
        },
        {
            "identified_line": {
                "line": "* Clinically significant cardiac arrhythmias (e.g. ventricular tachycardia), complete left bundle branch block, high-grade AV block (e.g. bifascicular block, Mobitz type II and third-degree AV block)",
                "criterions": [
                    {
                        "exact_snippets": "Clinically significant cardiac arrhythmias (e.g. ventricular tachycardia)",
                        "criterion": "cardiac arrhythmias",
                        "requirement": {
                            "requirement_type": "severity",
                            "expected_value": "clinically significant"
                        }
                    },
                    {
                        "exact_snippets": "complete left bundle branch block",
                        "criterion": "left bundle branch block",
                        "requirement": {
                            "requirement_type": "completeness",
                            "expected_value": "complete"
                        }
                    },
                    {
                        "exact_snippets": "high-grade AV block (e.g. bifascicular block, Mobitz type II and third-degree AV block)",
                        "criterion": "AV block",
                        "requirement": {
                            "requirement_type": "grade",
                            "expected_value": "high-grade"
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "Clinically significant cardiac arrhythmias (e.g. ventricular tachycardia)",
                        "criterion": "cardiac arrhythmias",
                        "requirement": {
                            "requirement_type": "severity",
                            "expected_value": "clinically significant"
                        }
                    },
                    {
                        "exact_snippets": "complete left bundle branch block",
                        "criterion": "left bundle branch block",
                        "requirement": {
                            "requirement_type": "completeness",
                            "expected_value": "complete"
                        }
                    },
                    {
                        "exact_snippets": "high-grade AV block (e.g. bifascicular block, Mobitz type II and third-degree AV block)",
                        "criterion": "AV block",
                        "requirement": {
                            "requirement_type": "grade",
                            "expected_value": "high-grade"
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "* Clinically significant, uncontrolled heart disease and/or cardiac repolarization abnormalities, including any of the following:",
                "criterions": [
                    {
                        "exact_snippets": "Clinically significant, uncontrolled heart disease",
                        "criterion": "heart disease",
                        "requirement": {
                            "requirement_type": "clinical significance",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "Clinically significant, uncontrolled heart disease",
                        "criterion": "heart disease",
                        "requirement": {
                            "requirement_type": "control status",
                            "expected_value": "uncontrolled"
                        }
                    },
                    {
                        "exact_snippets": "cardiac repolarization abnormalities",
                        "criterion": "cardiac repolarization abnormalities",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    }
                ]
            },
            "logical_structure": {
                "or_criteria": [
                    {
                        "and_criteria": [
                            {
                                "exact_snippets": "Clinically significant, uncontrolled heart disease",
                                "criterion": "heart disease",
                                "requirement": {
                                    "requirement_type": "clinical significance",
                                    "expected_value": true
                                }
                            },
                            {
                                "exact_snippets": "Clinically significant, uncontrolled heart disease",
                                "criterion": "heart disease",
                                "requirement": {
                                    "requirement_type": "control status",
                                    "expected_value": "uncontrolled"
                                }
                            }
                        ]
                    },
                    {
                        "exact_snippets": "cardiac repolarization abnormalities",
                        "criterion": "cardiac repolarization abnormalities",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "* Clinically stable CNS tumor at the time of screening and not receiving steroids and/or enzyme-inducing anti-epileptic medications for brain metastases.",
                "criterions": [
                    {
                        "exact_snippets": "Clinically stable CNS tumor at the time of screening",
                        "criterion": "CNS tumor",
                        "requirement": {
                            "requirement_type": "clinical stability",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "Clinically stable CNS tumor at the time of screening",
                        "criterion": "CNS tumor",
                        "requirement": {
                            "requirement_type": "time",
                            "expected_value": "at the time of screening"
                        }
                    },
                    {
                        "exact_snippets": "not receiving steroids ... for brain metastases",
                        "criterion": "steroid use for brain metastases",
                        "requirement": {
                            "requirement_type": "current use",
                            "expected_value": false
                        }
                    },
                    {
                        "exact_snippets": "not receiving ... enzyme-inducing anti-epileptic medications for brain metastases",
                        "criterion": "enzyme-inducing anti-epileptic medication use for brain metastases",
                        "requirement": {
                            "requirement_type": "current use",
                            "expected_value": false
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "and_criteria": [
                            {
                                "exact_snippets": "Clinically stable CNS tumor at the time of screening",
                                "criterion": "CNS tumor",
                                "requirement": {
                                    "requirement_type": "clinical stability",
                                    "expected_value": true
                                }
                            },
                            {
                                "exact_snippets": "Clinically stable CNS tumor at the time of screening",
                                "criterion": "CNS tumor",
                                "requirement": {
                                    "requirement_type": "time",
                                    "expected_value": "at the time of screening"
                                }
                            }
                        ]
                    },
                    {
                        "or_criteria": [
                            {
                                "exact_snippets": "not receiving steroids ... for brain metastases",
                                "criterion": "steroid use for brain metastases",
                                "requirement": {
                                    "requirement_type": "current use",
                                    "expected_value": false
                                }
                            },
                            {
                                "exact_snippets": "not receiving ... enzyme-inducing anti-epileptic medications for brain metastases",
                                "criterion": "enzyme-inducing anti-epileptic medication use for brain metastases",
                                "requirement": {
                                    "requirement_type": "current use",
                                    "expected_value": false
                                }
                            }
                        ]
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "* Women who are pregnant or breastfeeding.",
                "criterions": [
                    {
                        "exact_snippets": "Women who are pregnant",
                        "criterion": "pregnancy status",
                        "requirement": {
                            "requirement_type": "pregnant",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "Women who are ... breastfeeding",
                        "criterion": "breastfeeding status",
                        "requirement": {
                            "requirement_type": "breastfeeding",
                            "expected_value": true
                        }
                    }
                ]
            },
            "logical_structure": {
                "or_criteria": [
                    {
                        "exact_snippets": "Women who are pregnant",
                        "criterion": "pregnancy status",
                        "requirement": {
                            "requirement_type": "pregnant",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "Women who are ... breastfeeding",
                        "criterion": "breastfeeding status",
                        "requirement": {
                            "requirement_type": "breastfeeding",
                            "expected_value": true
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "* Risk factors for Torsades de Pointe (TdP) including uncorrected hypokalemia or hypomagnesemia, history of cardiac failure, or history of clinically significant/symptomatic bradycardia.",
                "criterions": [
                    {
                        "exact_snippets": "uncorrected hypokalemia",
                        "criterion": "hypokalemia",
                        "requirement": {
                            "requirement_type": "correction status",
                            "expected_value": "uncorrected"
                        }
                    },
                    {
                        "exact_snippets": "uncorrected ... hypomagnesemia",
                        "criterion": "hypomagnesemia",
                        "requirement": {
                            "requirement_type": "correction status",
                            "expected_value": "uncorrected"
                        }
                    },
                    {
                        "exact_snippets": "history of cardiac failure",
                        "criterion": "cardiac failure",
                        "requirement": {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "history of clinically significant/symptomatic bradycardia",
                        "criterion": "bradycardia",
                        "requirement": {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "history of clinically significant/symptomatic bradycardia",
                        "criterion": "bradycardia",
                        "requirement": {
                            "requirement_type": "severity",
                            "expected_value": "clinically significant/symptomatic"
                        }
                    }
                ]
            },
            "logical_structure": {
                "or_criteria": [
                    {
                        "or_criteria": [
                            {
                                "and_criteria": [
                                    {
                                        "exact_snippets": "uncorrected hypokalemia",
                                        "criterion": "hypokalemia",
                                        "requirement": {
                                            "requirement_type": "correction status",
                                            "expected_value": "uncorrected"
                                        }
                                    },
                                    {
                                        "exact_snippets": "uncorrected ... hypomagnesemia",
                                        "criterion": "hypomagnesemia",
                                        "requirement": {
                                            "requirement_type": "correction status",
                                            "expected_value": "uncorrected"
                                        }
                                    }
                                ]
                            },
                            {
                                "exact_snippets": "history of cardiac failure",
                                "criterion": "cardiac failure",
                                "requirement": {
                                    "requirement_type": "history",
                                    "expected_value": true
                                }
                            },
                            {
                                "and_criteria": [
                                    {
                                        "exact_snippets": "history of clinically significant/symptomatic bradycardia",
                                        "criterion": "bradycardia",
                                        "requirement": {
                                            "requirement_type": "history",
                                            "expected_value": true
                                        }
                                    },
                                    {
                                        "exact_snippets": "history of clinically significant/symptomatic bradycardia",
                                        "criterion": "bradycardia",
                                        "requirement": {
                                            "requirement_type": "severity",
                                            "expected_value": "clinically significant/symptomatic"
                                        }
                                    }
                                ]
                            }
                        ]
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "* Patients previously exposed to FAP inhibitors, DPP inhibitors, or monoclonal antibodies targeting anti-PD-1, anti-PD-L1, or anti-CTLA-4.",
                "criterions": [
                    {
                        "exact_snippets": "Patients previously exposed to FAP inhibitors",
                        "criterion": "exposure to FAP inhibitors",
                        "requirement": {
                            "requirement_type": "prior exposure",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "Patients previously exposed to ... DPP inhibitors",
                        "criterion": "exposure to DPP inhibitors",
                        "requirement": {
                            "requirement_type": "prior exposure",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "Patients previously exposed to ... monoclonal antibodies targeting anti-PD-1",
                        "criterion": "exposure to monoclonal antibodies targeting anti-PD-1",
                        "requirement": {
                            "requirement_type": "prior exposure",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "Patients previously exposed to ... monoclonal antibodies targeting ... anti-PD-L1",
                        "criterion": "exposure to monoclonal antibodies targeting anti-PD-L1",
                        "requirement": {
                            "requirement_type": "prior exposure",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "Patients previously exposed to ... monoclonal antibodies targeting ... anti-CTLA-4",
                        "criterion": "exposure to monoclonal antibodies targeting anti-CTLA-4",
                        "requirement": {
                            "requirement_type": "prior exposure",
                            "expected_value": true
                        }
                    }
                ]
            },
            "logical_structure": {
                "or_criteria": [
                    {
                        "exact_snippets": "Patients previously exposed to FAP inhibitors",
                        "criterion": "exposure to FAP inhibitors",
                        "requirement": {
                            "requirement_type": "prior exposure",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "Patients previously exposed to ... DPP inhibitors",
                        "criterion": "exposure to DPP inhibitors",
                        "requirement": {
                            "requirement_type": "prior exposure",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "Patients previously exposed to ... monoclonal antibodies targeting anti-PD-1",
                        "criterion": "exposure to monoclonal antibodies targeting anti-PD-1",
                        "requirement": {
                            "requirement_type": "prior exposure",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "Patients previously exposed to ... monoclonal antibodies targeting ... anti-PD-L1",
                        "criterion": "exposure to monoclonal antibodies targeting anti-PD-L1",
                        "requirement": {
                            "requirement_type": "prior exposure",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "Patients previously exposed to ... monoclonal antibodies targeting ... anti-CTLA-4",
                        "criterion": "exposure to monoclonal antibodies targeting anti-CTLA-4",
                        "requirement": {
                            "requirement_type": "prior exposure",
                            "expected_value": true
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "* Long QT syndrome or family history of idiopathic sudden death or congenital long QT syndrome, or any of the following:",
                "criterions": [
                    {
                        "exact_snippets": "Long QT syndrome",
                        "criterion": "Long QT syndrome",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "family history of idiopathic sudden death",
                        "criterion": "family history of idiopathic sudden death",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "congenital long QT syndrome",
                        "criterion": "congenital long QT syndrome",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    }
                ]
            },
            "logical_structure": {
                "or_criteria": [
                    {
                        "exact_snippets": "Long QT syndrome",
                        "criterion": "Long QT syndrome",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "family history of idiopathic sudden death",
                        "criterion": "family history of idiopathic sudden death",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "congenital long QT syndrome",
                        "criterion": "congenital long QT syndrome",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "* Patient has impairment of gastrointestinal (GI) function or GI disease that may significantly alter the absorption of the study drugs (e.g., ulcerative diseases, uncontrolled nausea, vomiting, diarrhea, malabsorption syndrome, or small bowel resection).",
                "criterions": [
                    {
                        "exact_snippets": "impairment of gastrointestinal (GI) function or GI disease that may significantly alter the absorption of the study drugs",
                        "criterion": "gastrointestinal (GI) function or GI disease",
                        "requirement": {
                            "requirement_type": "impairment or presence",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "impairment of gastrointestinal (GI) function or GI disease that may significantly alter the absorption of the study drugs",
                        "criterion": "gastrointestinal (GI) function or GI disease",
                        "requirement": {
                            "requirement_type": "potential to significantly alter absorption of study drugs",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "ulcerative diseases, uncontrolled nausea, vomiting, diarrhea, malabsorption syndrome, or small bowel resection",
                        "criterion": "ulcerative diseases",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "ulcerative diseases, uncontrolled nausea, vomiting, diarrhea, malabsorption syndrome, or small bowel resection",
                        "criterion": "uncontrolled nausea",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "ulcerative diseases, uncontrolled nausea, vomiting, diarrhea, malabsorption syndrome, or small bowel resection",
                        "criterion": "vomiting",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "ulcerative diseases, uncontrolled nausea, vomiting, diarrhea, malabsorption syndrome, or small bowel resection",
                        "criterion": "diarrhea",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "ulcerative diseases, uncontrolled nausea, vomiting, diarrhea, malabsorption syndrome, or small bowel resection",
                        "criterion": "malabsorption syndrome",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "ulcerative diseases, uncontrolled nausea, vomiting, diarrhea, malabsorption syndrome, or small bowel resection",
                        "criterion": "small bowel resection",
                        "requirement": {
                            "requirement_type": "history of procedure",
                            "expected_value": true
                        }
                    }
                ]
            },
            "logical_structure": {
                "or_criteria": [
                    {
                        "and_criteria": [
                            {
                                "exact_snippets": "impairment of gastrointestinal (GI) function or GI disease that may significantly alter the absorption of the study drugs",
                                "criterion": "gastrointestinal (GI) function or GI disease",
                                "requirement": {
                                    "requirement_type": "impairment or presence",
                                    "expected_value": true
                                }
                            },
                            {
                                "exact_snippets": "impairment of gastrointestinal (GI) function or GI disease that may significantly alter the absorption of the study drugs",
                                "criterion": "gastrointestinal (GI) function or GI disease",
                                "requirement": {
                                    "requirement_type": "potential to significantly alter absorption of study drugs",
                                    "expected_value": true
                                }
                            }
                        ]
                    },
                    {
                        "exact_snippets": "ulcerative diseases, uncontrolled nausea, vomiting, diarrhea, malabsorption syndrome, or small bowel resection",
                        "criterion": "ulcerative diseases",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "ulcerative diseases, uncontrolled nausea, vomiting, diarrhea, malabsorption syndrome, or small bowel resection",
                        "criterion": "uncontrolled nausea",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "ulcerative diseases, uncontrolled nausea, vomiting, diarrhea, malabsorption syndrome, or small bowel resection",
                        "criterion": "vomiting",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "ulcerative diseases, uncontrolled nausea, vomiting, diarrhea, malabsorption syndrome, or small bowel resection",
                        "criterion": "diarrhea",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "ulcerative diseases, uncontrolled nausea, vomiting, diarrhea, malabsorption syndrome, or small bowel resection",
                        "criterion": "malabsorption syndrome",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "ulcerative diseases, uncontrolled nausea, vomiting, diarrhea, malabsorption syndrome, or small bowel resection",
                        "criterion": "small bowel resection",
                        "requirement": {
                            "requirement_type": "history of procedure",
                            "expected_value": true
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "* History of acute coronary syndromes (including myocardial infarction, unstable angina, coronary artery bypass grafting, coronary angioplasty, or stenting) or symptomatic pericarditis within 6 months prior to screening",
                "criterions": [
                    {
                        "exact_snippets": "History of acute coronary syndromes (including myocardial infarction, unstable angina, coronary artery bypass grafting, coronary angioplasty, or stenting) ... within 6 months prior to screening",
                        "criterion": "acute coronary syndromes",
                        "requirement": {
                            "requirement_type": "history_within_timeframe",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": "<=",
                                        "value": 6,
                                        "unit": "months"
                                    }
                                ]
                            }
                        }
                    },
                    {
                        "exact_snippets": "symptomatic pericarditis within 6 months prior to screening",
                        "criterion": "symptomatic pericarditis",
                        "requirement": {
                            "requirement_type": "history_within_timeframe",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": "<=",
                                        "value": 6,
                                        "unit": "months"
                                    }
                                ]
                            }
                        }
                    }
                ]
            },
            "logical_structure": {
                "or_criteria": [
                    {
                        "exact_snippets": "History of acute coronary syndromes (including myocardial infarction, unstable angina, coronary artery bypass grafting, coronary angioplasty, or stenting) ... within 6 months prior to screening",
                        "criterion": "acute coronary syndromes",
                        "requirement": {
                            "requirement_type": "history_within_timeframe",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": "<=",
                                        "value": 6,
                                        "unit": "months"
                                    }
                                ]
                            }
                        }
                    },
                    {
                        "exact_snippets": "symptomatic pericarditis within 6 months prior to screening",
                        "criterion": "symptomatic pericarditis",
                        "requirement": {
                            "requirement_type": "history_within_timeframe",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": "<=",
                                        "value": 6,
                                        "unit": "months"
                                    }
                                ]
                            }
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "* History of documented congestive heart failure (New York Heart Association functional classification III-IV)",
                "criterions": [
                    {
                        "exact_snippets": "History of documented congestive heart failure",
                        "criterion": "congestive heart failure",
                        "requirement": {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "History of documented congestive heart failure",
                        "criterion": "congestive heart failure",
                        "requirement": {
                            "requirement_type": "documentation",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "New York Heart Association functional classification III-IV",
                        "criterion": "New York Heart Association functional classification",
                        "requirement": {
                            "requirement_type": "classification",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": ">=",
                                        "value": 3,
                                        "unit": ""
                                    },
                                    {
                                        "operator": "<=",
                                        "value": 4,
                                        "unit": ""
                                    }
                                ]
                            }
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "History of documented congestive heart failure",
                        "criterion": "congestive heart failure",
                        "requirement": {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "History of documented congestive heart failure",
                        "criterion": "congestive heart failure",
                        "requirement": {
                            "requirement_type": "documentation",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "New York Heart Association functional classification III-IV",
                        "criterion": "New York Heart Association functional classification",
                        "requirement": {
                            "requirement_type": "classification",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": ">=",
                                        "value": 3,
                                        "unit": ""
                                    },
                                    {
                                        "operator": "<=",
                                        "value": 4,
                                        "unit": ""
                                    }
                                ]
                            }
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "* Patient has any other concurrent severe and/or uncontrolled medical condition that would, in the investigator's judgment, cause unacceptable safety risks, contraindicate patient participation in the clinical study or compromise compliance with the protocol (e.g. chronic pancreatitis, chronic active hepatitis, active untreated or uncontrolled fungal, bacterial or viral infections, etc.).",
                "criterions": [
                    {
                        "exact_snippets": "any other concurrent severe and/or uncontrolled medical condition",
                        "criterion": "concurrent medical condition",
                        "requirement": {
                            "requirement_type": "severity",
                            "expected_value": "severe"
                        }
                    },
                    {
                        "exact_snippets": "any other concurrent severe and/or uncontrolled medical condition",
                        "criterion": "concurrent medical condition",
                        "requirement": {
                            "requirement_type": "control_status",
                            "expected_value": "uncontrolled"
                        }
                    },
                    {
                        "exact_snippets": "that would, in the investigator's judgment, cause unacceptable safety risks",
                        "criterion": "medical condition impact on safety",
                        "requirement": {
                            "requirement_type": "risk_level",
                            "expected_value": "unacceptable"
                        }
                    },
                    {
                        "exact_snippets": "that would...contraindicate patient participation in the clinical study",
                        "criterion": "medical condition contraindication to participation",
                        "requirement": {
                            "requirement_type": "contraindication",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "that would...compromise compliance with the protocol",
                        "criterion": "medical condition impact on protocol compliance",
                        "requirement": {
                            "requirement_type": "compliance_compromise",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "chronic pancreatitis",
                        "criterion": "chronic pancreatitis",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "chronic active hepatitis",
                        "criterion": "chronic active hepatitis",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "active untreated or uncontrolled fungal, bacterial or viral infections",
                        "criterion": "active fungal, bacterial or viral infections",
                        "requirement": {
                            "requirement_type": "treatment_status",
                            "expected_value": "untreated"
                        }
                    },
                    {
                        "exact_snippets": "active untreated or uncontrolled fungal, bacterial or viral infections",
                        "criterion": "active fungal, bacterial or viral infections",
                        "requirement": {
                            "requirement_type": "control_status",
                            "expected_value": "uncontrolled"
                        }
                    }
                ]
            },
            "logical_structure": {
                "or_criteria": [
                    {
                        "and_criteria": [
                            {
                                "or_criteria": [
                                    {
                                        "exact_snippets": "any other concurrent severe and/or uncontrolled medical condition",
                                        "criterion": "concurrent medical condition",
                                        "requirement": {
                                            "requirement_type": "severity",
                                            "expected_value": "severe"
                                        }
                                    },
                                    {
                                        "exact_snippets": "any other concurrent severe and/or uncontrolled medical condition",
                                        "criterion": "concurrent medical condition",
                                        "requirement": {
                                            "requirement_type": "control_status",
                                            "expected_value": "uncontrolled"
                                        }
                                    }
                                ]
                            },
                            {
                                "or_criteria": [
                                    {
                                        "exact_snippets": "that would, in the investigator's judgment, cause unacceptable safety risks",
                                        "criterion": "medical condition impact on safety",
                                        "requirement": {
                                            "requirement_type": "risk_level",
                                            "expected_value": "unacceptable"
                                        }
                                    },
                                    {
                                        "exact_snippets": "that would...contraindicate patient participation in the clinical study",
                                        "criterion": "medical condition contraindication to participation",
                                        "requirement": {
                                            "requirement_type": "contraindication",
                                            "expected_value": true
                                        }
                                    },
                                    {
                                        "exact_snippets": "that would...compromise compliance with the protocol",
                                        "criterion": "medical condition impact on protocol compliance",
                                        "requirement": {
                                            "requirement_type": "compliance_compromise",
                                            "expected_value": true
                                        }
                                    }
                                ]
                            }
                        ]
                    },
                    {
                        "exact_snippets": "chronic pancreatitis",
                        "criterion": "chronic pancreatitis",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "chronic active hepatitis",
                        "criterion": "chronic active hepatitis",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    },
                    {
                        "or_criteria": [
                            {
                                "exact_snippets": "active untreated or uncontrolled fungal, bacterial or viral infections",
                                "criterion": "active fungal, bacterial or viral infections",
                                "requirement": {
                                    "requirement_type": "treatment_status",
                                    "expected_value": "untreated"
                                }
                            },
                            {
                                "exact_snippets": "active untreated or uncontrolled fungal, bacterial or viral infections",
                                "criterion": "active fungal, bacterial or viral infections",
                                "requirement": {
                                    "requirement_type": "control_status",
                                    "expected_value": "uncontrolled"
                                }
                            }
                        ]
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "* Patients who have received a live-virus vaccination within 30 days of planned treatment start date.",
                "criterions": [
                    {
                        "exact_snippets": "received a live-virus vaccination within 30 days of planned treatment start date",
                        "criterion": "live-virus vaccination",
                        "requirement": {
                            "requirement_type": "time since vaccination before treatment start",
                            "expected_value": {
                                "operator": ">=",
                                "value": 30,
                                "unit": "days"
                            }
                        }
                    }
                ]
            },
            "logical_structure": {
                "not_criteria": {
                    "exact_snippets": "received a live-virus vaccination within 30 days of planned treatment start date",
                    "criterion": "live-virus vaccination",
                    "requirement": {
                        "requirement_type": "time since vaccination before treatment start",
                        "expected_value": {
                            "operator": ">=",
                            "value": 30,
                            "unit": "days"
                        }
                    }
                }
            }
        },
        {
            "identified_line": {
                "line": "* Patients with history of symptomatic orthostatic hypotension within 3 months prior to enrollment, defined as a drop in systolic blood pressure (SBP) of ≥ 20 mmHg or diastolic blood pressure (DBP) of ≥ 10 mmHg with assumption of an upright posture.",
                "criterions": [
                    {
                        "exact_snippets": "history of symptomatic orthostatic hypotension within 3 months prior to enrollment",
                        "criterion": "symptomatic orthostatic hypotension",
                        "requirement": {
                            "requirement_type": "history_within_timeframe",
                            "expected_value": {
                                "operator": "<=",
                                "value": 3,
                                "unit": "months prior to enrollment"
                            }
                        }
                    },
                    {
                        "exact_snippets": "a drop in systolic blood pressure (SBP) of ≥ 20 mmHg ... with assumption of an upright posture",
                        "criterion": "systolic blood pressure drop upon standing",
                        "requirement": {
                            "requirement_type": "change_with_posture",
                            "expected_value": {
                                "operator": ">=",
                                "value": 20,
                                "unit": "mmHg"
                            }
                        }
                    },
                    {
                        "exact_snippets": "a drop in ... diastolic blood pressure (DBP) of ≥ 10 mmHg with assumption of an upright posture",
                        "criterion": "diastolic blood pressure drop upon standing",
                        "requirement": {
                            "requirement_type": "change_with_posture",
                            "expected_value": {
                                "operator": ">=",
                                "value": 10,
                                "unit": "mmHg"
                            }
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "and_criteria": [
                            {
                                "exact_snippets": "history of symptomatic orthostatic hypotension within 3 months prior to enrollment",
                                "criterion": "symptomatic orthostatic hypotension",
                                "requirement": {
                                    "requirement_type": "history_within_timeframe",
                                    "expected_value": {
                                        "operator": "<=",
                                        "value": 3,
                                        "unit": "months prior to enrollment"
                                    }
                                }
                            },
                            {
                                "or_criteria": [
                                    {
                                        "exact_snippets": "a drop in systolic blood pressure (SBP) of ≥ 20 mmHg ... with assumption of an upright posture",
                                        "criterion": "systolic blood pressure drop upon standing",
                                        "requirement": {
                                            "requirement_type": "change_with_posture",
                                            "expected_value": {
                                                "operator": ">=",
                                                "value": 20,
                                                "unit": "mmHg"
                                            }
                                        }
                                    },
                                    {
                                        "exact_snippets": "a drop in ... diastolic blood pressure (DBP) of ≥ 10 mmHg with assumption of an upright posture",
                                        "criterion": "diastolic blood pressure drop upon standing",
                                        "requirement": {
                                            "requirement_type": "change_with_posture",
                                            "expected_value": {
                                                "operator": ">=",
                                                "value": 10,
                                                "unit": "mmHg"
                                            }
                                        }
                                    }
                                ]
                            }
                        ]
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "* Patient has a known history of HIV infection or chronic, active hepatitis B or C (testing is not mandatory) - patients with hepatitis C status-post treatment with undetectable viral load are eligible.",
                "criterions": [
                    {
                        "exact_snippets": "known history of HIV infection",
                        "criterion": "HIV infection",
                        "requirement": {
                            "requirement_type": "history",
                            "expected_value": false
                        }
                    },
                    {
                        "exact_snippets": "chronic, active hepatitis B",
                        "criterion": "hepatitis B infection",
                        "requirement": {
                            "requirement_type": "chronic active infection",
                            "expected_value": false
                        }
                    },
                    {
                        "exact_snippets": "chronic, active hepatitis C",
                        "criterion": "hepatitis C infection",
                        "requirement": {
                            "requirement_type": "chronic active infection",
                            "expected_value": false
                        }
                    },
                    {
                        "exact_snippets": "hepatitis C status-post treatment with undetectable viral load are eligible",
                        "criterion": "hepatitis C infection (treated)",
                        "requirement": {
                            "requirement_type": "treatment status",
                            "expected_value": "status-post treatment"
                        }
                    },
                    {
                        "exact_snippets": "hepatitis C status-post treatment with undetectable viral load are eligible",
                        "criterion": "hepatitis C infection (treated)",
                        "requirement": {
                            "requirement_type": "viral load",
                            "expected_value": "undetectable"
                        }
                    }
                ]
            },
            "logical_structure": {
                "or_criteria": [
                    {
                        "not_criteria": {
                            "exact_snippets": "known history of HIV infection",
                            "criterion": "HIV infection",
                            "requirement": {
                                "requirement_type": "history",
                                "expected_value": false
                            }
                        }
                    },
                    {
                        "not_criteria": {
                            "exact_snippets": "chronic, active hepatitis B",
                            "criterion": "hepatitis B infection",
                            "requirement": {
                                "requirement_type": "chronic active infection",
                                "expected_value": false
                            }
                        }
                    },
                    {
                        "or_criteria": [
                            {
                                "and_criteria": [
                                    {
                                        "not_criteria": {
                                            "exact_snippets": "chronic, active hepatitis C",
                                            "criterion": "hepatitis C infection",
                                            "requirement": {
                                                "requirement_type": "chronic active infection",
                                                "expected_value": false
                                            }
                                        }
                                    },
                                    {
                                        "not_criteria": {
                                            "and_criteria": [
                                                {
                                                    "exact_snippets": "hepatitis C status-post treatment with undetectable viral load are eligible",
                                                    "criterion": "hepatitis C infection (treated)",
                                                    "requirement": {
                                                        "requirement_type": "treatment status",
                                                        "expected_value": "status-post treatment"
                                                    }
                                                },
                                                {
                                                    "exact_snippets": "hepatitis C status-post treatment with undetectable viral load are eligible",
                                                    "criterion": "hepatitis C infection (treated)",
                                                    "requirement": {
                                                        "requirement_type": "viral load",
                                                        "expected_value": "undetectable"
                                                    }
                                                }
                                            ]
                                        }
                                    }
                                ]
                            }
                        ]
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "* Patients with a history of (non-infectious) pneumonitis that required steroids, current pneumonitis, or those who have a history of interstitial lung disease.",
                "criterions": [
                    {
                        "exact_snippets": "history of (non-infectious) pneumonitis that required steroids",
                        "criterion": "history of non-infectious pneumonitis",
                        "requirement": {
                            "requirement_type": "treatment requirement",
                            "expected_value": "required steroids"
                        }
                    },
                    {
                        "exact_snippets": "current pneumonitis",
                        "criterion": "current pneumonitis",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "history of interstitial lung disease",
                        "criterion": "history of interstitial lung disease",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    }
                ]
            },
            "logical_structure": {
                "or_criteria": [
                    {
                        "exact_snippets": "history of (non-infectious) pneumonitis that required steroids",
                        "criterion": "history of non-infectious pneumonitis",
                        "requirement": {
                            "requirement_type": "treatment requirement",
                            "expected_value": "required steroids"
                        }
                    },
                    {
                        "exact_snippets": "current pneumonitis",
                        "criterion": "current pneumonitis",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "history of interstitial lung disease",
                        "criterion": "history of interstitial lung disease",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    }
                ]
            }
        }
    ],
    "miscellaneous_lines": [],
    "failed_inclusion": [
        {
            "identified_line": {
                "line": "* Renal function: serum creatinine ≤ 1.5 × upper normal limit of institution's normal range or creatinine clearance ≥ 50 mL/min/1.73 m2 for subjects with creatinine levels above institutional normal",
                "criterions": [
                    {
                        "exact_snippets": "serum creatinine ≤ 1.5 × upper normal limit of institution's normal range",
                        "criterion": "serum creatinine",
                        "requirement": {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<=",
                                "value": 1.5,
                                "unit": "times upper normal limit of institution's normal range"
                            }
                        }
                    },
                    {
                        "exact_snippets": "creatinine clearance ≥ 50 mL/min/1.73 m2 for subjects with creatinine levels above institutional normal",
                        "criterion": "creatinine clearance",
                        "requirement": {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 50,
                                "unit": "mL/min/1.73 m2"
                            }
                        }
                    }
                ]
            },
            "logical_structure": {
                "or_criteria": [
                    {
                        "exact_snippets": "serum creatinine ≤ 1.5 × upper normal limit of institution's normal range",
                        "criterion": "serum creatinine",
                        "requirement": {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<=",
                                "value": 1.5,
                                "unit": "times upper normal limit of institution's normal range"
                            }
                        }
                    },
                    {
                        "condition": {
                            "exact_snippets": "serum creatinine ≤ 1.5 × upper normal limit of institution's normal range",
                            "criterion": "serum creatinine",
                            "requirement": {
                                "requirement_type": "quantity",
                                "expected_value": {
                                    "operator": ">",
                                    "value": 1,
                                    "unit": "times upper normal limit of institution's normal range"
                                }
                            }
                        },
                        "then_criteria": {
                            "exact_snippets": "creatinine clearance ≥ 50 mL/min/1.73 m2 for subjects with creatinine levels above institutional normal",
                            "criterion": "creatinine clearance",
                            "requirement": {
                                "requirement_type": "quantity",
                                "expected_value": {
                                    "operator": ">=",
                                    "value": 50,
                                    "unit": "mL/min/1.73 m2"
                                }
                            }
                        },
                        "else_criteria": null
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "* Age ≥ 18 years",
                "criterions": [
                    {
                        "exact_snippets": "Age ≥ 18 years",
                        "criterion": "age",
                        "requirement": {
                            "requirement_type": "minimum value",
                            "expected_value": {
                                "operator": ">=",
                                "value": 18,
                                "unit": "years"
                            }
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "Age  18 years",
                        "criterion": "age",
                        "requirement": {
                            "requirement_type": "minimum value",
                            "expected_value": {
                                "operator": ">=",
                                "value": 18,
                                "unit": "years"
                            }
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "* Women of childbearing potential must have a negative serum pregnancy test during the screening period and on C1D1 and/or postmenopausal women must be amenorrheic for at least 12 months to be considered of non-childbearing potential",
                "criterions": [
                    {
                        "exact_snippets": "Women of childbearing potential must have a negative serum pregnancy test during the screening period and on C1D1",
                        "criterion": "serum pregnancy test",
                        "requirement": {
                            "requirement_type": "result",
                            "expected_value": "negative"
                        }
                    },
                    {
                        "exact_snippets": "Women of childbearing potential must have a negative serum pregnancy test during the screening period and on C1D1",
                        "criterion": "serum pregnancy test",
                        "requirement": {
                            "requirement_type": "timing",
                            "expected_value": [
                                "screening period",
                                "C1D1"
                            ]
                        }
                    },
                    {
                        "exact_snippets": "postmenopausal women must be amenorrheic for at least 12 months to be considered of non-childbearing potential",
                        "criterion": "amenorrhea duration",
                        "requirement": {
                            "requirement_type": "duration",
                            "expected_value": {
                                "operator": ">=",
                                "value": 12,
                                "unit": "months"
                            }
                        }
                    }
                ]
            },
            "logical_structure": {
                "exact_snippets": "failed",
                "criterion": "failed",
                "requirement": {
                    "requirement_type": "failed",
                    "expected_value": "failed"
                }
            }
        },
        {
            "identified_line": {
                "line": "* Bone marrow function: absolute neutrophil count (ANC) ≥ 1,500/mm3; Platelets ≥100 × 109/L; hemoglobin ≥ 8.0 g/dL (with no prior red blood cell transfusions during the prior 14 days)",
                "criterions": [
                    {
                        "exact_snippets": "absolute neutrophil count (ANC) ≥ 1,500/mm3",
                        "criterion": "absolute neutrophil count (ANC)",
                        "requirement": {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 1500,
                                "unit": "mm3"
                            }
                        }
                    },
                    {
                        "exact_snippets": "Platelets ≥100 × 10^9/L",
                        "criterion": "platelet count",
                        "requirement": {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 100,
                                "unit": "10^9/L"
                            }
                        }
                    },
                    {
                        "exact_snippets": "hemoglobin ≥ 8.0 g/dL (with no prior red blood cell transfusions during the prior 14 days)",
                        "criterion": "hemoglobin",
                        "requirement": {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 8.0,
                                "unit": "g/dL"
                            }
                        }
                    },
                    {
                        "exact_snippets": "hemoglobin ≥ 8.0 g/dL (with no prior red blood cell transfusions during the prior 14 days)",
                        "criterion": "hemoglobin",
                        "requirement": {
                            "requirement_type": "prior red blood cell transfusions during the prior 14 days",
                            "expected_value": false
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "absolute neutrophil count (ANC) \u001e 1,500/mm3",
                        "criterion": "absolute neutrophil count (ANC)",
                        "requirement": {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 1500,
                                "unit": "mm3"
                            }
                        }
                    },
                    {
                        "exact_snippets": "Platelets \u001e100 \u0000d 10^9/L",
                        "criterion": "platelet count",
                        "requirement": {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 100,
                                "unit": "10^9/L"
                            }
                        }
                    },
                    {
                        "and_criteria": [
                            {
                                "exact_snippets": "hemoglobin \u001e 8.0 g/dL (with no prior red blood cell transfusions during the prior 14 days)",
                                "criterion": "hemoglobin",
                                "requirement": {
                                    "requirement_type": "quantity",
                                    "expected_value": {
                                        "operator": ">=",
                                        "value": 8.0,
                                        "unit": "g/dL"
                                    }
                                }
                            },
                            {
                                "exact_snippets": "hemoglobin \u001e 8.0 g/dL (with no prior red blood cell transfusions during the prior 14 days)",
                                "criterion": "hemoglobin",
                                "requirement": {
                                    "requirement_type": "prior red blood cell transfusions during the prior 14 days",
                                    "expected_value": false
                                }
                            }
                        ]
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "* Patient's acute toxic effects of previous anticancer therapy have resolved to ≤ Grade 1 except for Grade 2-3 peripheral neuropathy or any grade of alopecia.",
                "criterions": [
                    {
                        "exact_snippets": "acute toxic effects of previous anticancer therapy have resolved to ≤ Grade 1",
                        "criterion": "acute toxic effects of previous anticancer therapy",
                        "requirement": {
                            "requirement_type": "severity",
                            "expected_value": {
                                "operator": "<=",
                                "value": 1,
                                "unit": "Grade"
                            }
                        }
                    },
                    {
                        "exact_snippets": "except for Grade 2-3 peripheral neuropathy",
                        "criterion": "peripheral neuropathy",
                        "requirement": {
                            "requirement_type": "severity",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": ">=",
                                        "value": 2,
                                        "unit": "Grade"
                                    },
                                    {
                                        "operator": "<=",
                                        "value": 3,
                                        "unit": "Grade"
                                    }
                                ]
                            }
                        }
                    },
                    {
                        "exact_snippets": "any grade of alopecia",
                        "criterion": "alopecia",
                        "requirement": {
                            "requirement_type": "severity",
                            "expected_value": "any grade"
                        }
                    }
                ]
            },
            "logical_structure": {
                "or_criteria": [
                    {
                        "and_criteria": [
                            {
                                "exact_snippets": "acute toxic effects of previous anticancer therapy have resolved to \u0010e Grade 1",
                                "criterion": "acute toxic effects of previous anticancer therapy",
                                "requirement": {
                                    "requirement_type": "severity",
                                    "expected_value": {
                                        "operator": "<=",
                                        "value": 1,
                                        "unit": "Grade"
                                    }
                                }
                            },
                            {
                                "exact_snippets": "any grade of alopecia",
                                "criterion": "alopecia",
                                "requirement": {
                                    "requirement_type": "severity",
                                    "expected_value": "any grade"
                                }
                            }
                        ]
                    },
                    {
                        "and_criteria": [
                            {
                                "exact_snippets": "acute toxic effects of previous anticancer therapy have resolved to \u0010e Grade 1",
                                "criterion": "acute toxic effects of previous anticancer therapy",
                                "requirement": {
                                    "requirement_type": "severity",
                                    "expected_value": {
                                        "operator": "<=",
                                        "value": 1,
                                        "unit": "Grade"
                                    }
                                }
                            },
                            {
                                "exact_snippets": "except for Grade 2-3 peripheral neuropathy",
                                "criterion": "peripheral neuropathy",
                                "requirement": {
                                    "requirement_type": "severity",
                                    "expected_value": {
                                        "comparisons": [
                                            {
                                                "operator": ">=",
                                                "value": 2,
                                                "unit": "Grade"
                                            },
                                            {
                                                "operator": "<=",
                                                "value": 3,
                                                "unit": "Grade"
                                            }
                                        ]
                                    }
                                }
                            }
                        ]
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "* Measurable disease by iRECIST v. 1.1 criteria (tumor ≥ 1 cm in longest diameter on axial image on CT or MRI and/or lymph node(s) ≥ 1.5 cm in short axis on CT or MRI) on baseline imaging",
                "criterions": [
                    {
                        "exact_snippets": "Measurable disease by iRECIST v. 1.1 criteria",
                        "criterion": "measurable disease",
                        "requirement": {
                            "requirement_type": "assessment_method",
                            "expected_value": "iRECIST v. 1.1 criteria"
                        }
                    },
                    {
                        "exact_snippets": "tumor ≥ 1 cm in longest diameter on axial image on CT or MRI",
                        "criterion": "tumor size",
                        "requirement": {
                            "requirement_type": "location",
                            "expected_value": "axial image on CT or MRI"
                        }
                    },
                    {
                        "exact_snippets": "tumor ≥ 1 cm in longest diameter on axial image on CT or MRI",
                        "criterion": "tumor size",
                        "requirement": {
                            "requirement_type": "dimension",
                            "expected_value": {
                                "operator": ">=",
                                "value": 1,
                                "unit": "cm"
                            }
                        }
                    },
                    {
                        "exact_snippets": "tumor ≥ 1 cm in longest diameter on axial image on CT or MRI",
                        "criterion": "tumor size",
                        "requirement": {
                            "requirement_type": "measurement_axis",
                            "expected_value": "longest diameter"
                        }
                    },
                    {
                        "exact_snippets": "lymph node(s) ≥ 1.5 cm in short axis on CT or MRI",
                        "criterion": "lymph node size",
                        "requirement": {
                            "requirement_type": "location",
                            "expected_value": "CT or MRI"
                        }
                    },
                    {
                        "exact_snippets": "lymph node(s) ≥ 1.5 cm in short axis on CT or MRI",
                        "criterion": "lymph node size",
                        "requirement": {
                            "requirement_type": "dimension",
                            "expected_value": {
                                "operator": ">=",
                                "value": 1.5,
                                "unit": "cm"
                            }
                        }
                    },
                    {
                        "exact_snippets": "lymph node(s) ≥ 1.5 cm in short axis on CT or MRI",
                        "criterion": "lymph node size",
                        "requirement": {
                            "requirement_type": "measurement_axis",
                            "expected_value": "short axis"
                        }
                    },
                    {
                        "exact_snippets": "on baseline imaging",
                        "criterion": "imaging timing",
                        "requirement": {
                            "requirement_type": "timing",
                            "expected_value": "baseline"
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "and_criteria": [
                            {
                                "exact_snippets": "Measurable disease by iRECIST v. 1.1 criteria",
                                "criterion": "measurable disease",
                                "requirement": {
                                    "requirement_type": "assessment_method",
                                    "expected_value": "iRECIST v. 1.1 criteria"
                                }
                            },
                            {
                                "exact_snippets": "on baseline imaging",
                                "criterion": "imaging timing",
                                "requirement": {
                                    "requirement_type": "timing",
                                    "expected_value": "baseline"
                                }
                            }
                        ]
                    },
                    {
                        "or_criteria": [
                            {
                                "and_criteria": [
                                    {
                                        "exact_snippets": "tumor \u001e 1 cm in longest diameter on axial image on CT or MRI",
                                        "criterion": "tumor size",
                                        "requirement": {
                                            "requirement_type": "location",
                                            "expected_value": "axial image on CT or MRI"
                                        }
                                    },
                                    {
                                        "exact_snippets": "tumor \u001e 1 cm in longest diameter on axial image on CT or MRI",
                                        "criterion": "tumor size",
                                        "requirement": {
                                            "requirement_type": "dimension",
                                            "expected_value": {
                                                "operator": ">=",
                                                "value": 1,
                                                "unit": "cm"
                                            }
                                        }
                                    },
                                    {
                                        "exact_snippets": "tumor \u001e 1 cm in longest diameter on axial image on CT or MRI",
                                        "criterion": "tumor size",
                                        "requirement": {
                                            "requirement_type": "measurement_axis",
                                            "expected_value": "longest diameter"
                                        }
                                    }
                                ]
                            },
                            {
                                "and_criteria": [
                                    {
                                        "exact_snippets": "lymph node(s) \u001e 1.5 cm in short axis on CT or MRI",
                                        "criterion": "lymph node size",
                                        "requirement": {
                                            "requirement_type": "location",
                                            "expected_value": "CT or MRI"
                                        }
                                    },
                                    {
                                        "exact_snippets": "lymph node(s) \u001e 1.5 cm in short axis on CT or MRI",
                                        "criterion": "lymph node size",
                                        "requirement": {
                                            "requirement_type": "dimension",
                                            "expected_value": {
                                                "operator": ">=",
                                                "value": 1.5,
                                                "unit": "cm"
                                            }
                                        }
                                    },
                                    {
                                        "exact_snippets": "lymph node(s) \u001e 1.5 cm in short axis on CT or MRI",
                                        "criterion": "lymph node size",
                                        "requirement": {
                                            "requirement_type": "measurement_axis",
                                            "expected_value": "short axis"
                                        }
                                    }
                                ]
                            }
                        ]
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "* Subjects with no brain metastases or a history of previously treated brain metastases who have been treated by surgery or stereotactic radiosurgery (SRS) at least 4 weeks prior to enrollment and have a baseline MRI that shows no evidence of active intracranial disease",
                "criterions": [
                    {
                        "exact_snippets": "no brain metastases",
                        "criterion": "brain metastases",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": false
                        }
                    },
                    {
                        "exact_snippets": "history of previously treated brain metastases ... treated by surgery or stereotactic radiosurgery (SRS)",
                        "criterion": "previously treated brain metastases",
                        "requirement": {
                            "requirement_type": "treatment type",
                            "expected_value": [
                                "surgery",
                                "stereotactic radiosurgery"
                            ]
                        }
                    },
                    {
                        "exact_snippets": "treated by surgery or stereotactic radiosurgery (SRS) at least 4 weeks prior to enrollment",
                        "criterion": "treatment timing for brain metastases",
                        "requirement": {
                            "requirement_type": "time since treatment",
                            "expected_value": {
                                "operator": ">=",
                                "value": 4,
                                "unit": "weeks"
                            }
                        }
                    },
                    {
                        "exact_snippets": "baseline MRI that shows no evidence of active intracranial disease",
                        "criterion": "active intracranial disease on baseline MRI",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": false
                        }
                    }
                ]
            },
            "logical_structure": {
                "exact_snippets": "failed",
                "criterion": "failed",
                "requirement": {
                    "requirement_type": "failed",
                    "expected_value": "failed"
                }
            }
        },
        {
            "identified_line": {
                "line": "* Male patients and their female partners of childbearing potential must agree and commit to use a barrier contraception (e.g., condom with spermicidal foam/gel/film/cream/ suppository) throughout the duration of the study until at least 6 months following the last dose of study drug, in addition to their female partners using either an intrauterine device or hormonal contraception and continuing until at least 6 months following the last dose of study drug. This criterion may be waived for male patients who have had a vasectomy >6 months before signing the informed consent form.",
                "criterions": [
                    {
                        "exact_snippets": "Male patients and their female partners of childbearing potential must agree and commit to use a barrier contraception (e.g., condom with spermicidal foam/gel/film/cream/ suppository) throughout the duration of the study until at least 6 months following the last dose of study drug",
                        "criterion": "contraception use by male patients and their female partners of childbearing potential",
                        "requirement": {
                            "requirement_type": "agreement to use barrier contraception",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "Male patients and their female partners of childbearing potential must agree and commit to use a barrier contraception (e.g., condom with spermicidal foam/gel/film/cream/ suppository) throughout the duration of the study until at least 6 months following the last dose of study drug",
                        "criterion": "contraception use by male patients and their female partners of childbearing potential",
                        "requirement": {
                            "requirement_type": "duration of contraception use",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": ">=",
                                        "value": 6,
                                        "unit": "months"
                                    }
                                ]
                            }
                        }
                    },
                    {
                        "exact_snippets": "their female partners using either an intrauterine device or hormonal contraception and continuing until at least 6 months following the last dose of study drug",
                        "criterion": "contraception use by female partners of male patients",
                        "requirement": {
                            "requirement_type": "contraception method",
                            "expected_value": [
                                "intrauterine device",
                                "hormonal contraception"
                            ]
                        }
                    },
                    {
                        "exact_snippets": "their female partners using either an intrauterine device or hormonal contraception and continuing until at least 6 months following the last dose of study drug",
                        "criterion": "contraception use by female partners of male patients",
                        "requirement": {
                            "requirement_type": "duration of contraception use",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": ">=",
                                        "value": 6,
                                        "unit": "months"
                                    }
                                ]
                            }
                        }
                    },
                    {
                        "exact_snippets": "This criterion may be waived for male patients who have had a vasectomy >6 months before signing the informed consent form",
                        "criterion": "vasectomy status of male patients",
                        "requirement": {
                            "requirement_type": "vasectomy performed",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "This criterion may be waived for male patients who have had a vasectomy >6 months before signing the informed consent form",
                        "criterion": "vasectomy status of male patients",
                        "requirement": {
                            "requirement_type": "time since vasectomy",
                            "expected_value": {
                                "operator": ">",
                                "value": 6,
                                "unit": "months"
                            }
                        }
                    }
                ]
            },
            "logical_structure": {
                "exact_snippets": "failed",
                "criterion": "failed",
                "requirement": {
                    "requirement_type": "failed",
                    "expected_value": "failed"
                }
            }
        }
    ],
    "failed_exclusion": [
        {
            "identified_line": {
                "line": "* Patient must not have active known or suspected autoimmune disease requiring systemic treatment in the past 2 years (i.e., with use of disease modifying agents, corticosteroids, or immunosuppressive drugs). Subjects with type I diabetes mellitus, hypothyroidism only requiring hormone replacement, skin disorders (such as vitiligo, psoriasis, or alopecia) not requiring systemic treatment, or conditions not expected to recur in the absence of an external trigger (e.g., celiac disease) are permitted to enroll.",
                "criterions": [
                    {
                        "exact_snippets": "must not have active known or suspected autoimmune disease requiring systemic treatment in the past 2 years (i.e., with use of disease modifying agents, corticosteroids, or immunosuppressive drugs)",
                        "criterion": "autoimmune disease",
                        "requirement": {
                            "requirement_type": "activity",
                            "expected_value": false
                        }
                    },
                    {
                        "exact_snippets": "must not have active known or suspected autoimmune disease requiring systemic treatment in the past 2 years (i.e., with use of disease modifying agents, corticosteroids, or immunosuppressive drugs)",
                        "criterion": "autoimmune disease",
                        "requirement": {
                            "requirement_type": "diagnosis certainty",
                            "expected_value": [
                                "known",
                                "suspected"
                            ]
                        }
                    },
                    {
                        "exact_snippets": "must not have active known or suspected autoimmune disease requiring systemic treatment in the past 2 years (i.e., with use of disease modifying agents, corticosteroids, or immunosuppressive drugs)",
                        "criterion": "autoimmune disease",
                        "requirement": {
                            "requirement_type": "systemic treatment requirement (past 2 years)",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "Subjects with type I diabetes mellitus ... are permitted to enroll",
                        "criterion": "type I diabetes mellitus",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "hypothyroidism only requiring hormone replacement ... are permitted to enroll",
                        "criterion": "hypothyroidism",
                        "requirement": {
                            "requirement_type": "treatment requirement",
                            "expected_value": "hormone replacement only"
                        }
                    },
                    {
                        "exact_snippets": "skin disorders (such as vitiligo, psoriasis, or alopecia) not requiring systemic treatment ... are permitted to enroll",
                        "criterion": "skin disorders (vitiligo, psoriasis, alopecia)",
                        "requirement": {
                            "requirement_type": "systemic treatment requirement",
                            "expected_value": false
                        }
                    },
                    {
                        "exact_snippets": "conditions not expected to recur in the absence of an external trigger (e.g., celiac disease) are permitted to enroll",
                        "criterion": "autoimmune conditions not expected to recur without external trigger (e.g., celiac disease)",
                        "requirement": {
                            "requirement_type": "recurrence expectation without external trigger",
                            "expected_value": false
                        }
                    }
                ]
            },
            "logical_structure": {
                "exact_snippets": "failed",
                "criterion": "failed",
                "requirement": {
                    "requirement_type": "failed",
                    "expected_value": "failed"
                }
            }
        },
        {
            "identified_line": {
                "line": "* Concurrent malignancy or malignancy within 2 years prior to C1D1, with the exception of adequately treated cutaneous basal or squamous cell carcinoma, non-melanomatous skin cancer, curatively resected cervical cancer, or any locally treated malignancy deemed low likelihood for recurrence or metastasis by the investigator.",
                "criterions": [
                    {
                        "exact_snippets": "Concurrent malignancy or malignancy within 2 years prior to C1D1",
                        "criterion": "malignancy",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": false
                        }
                    },
                    {
                        "exact_snippets": "Concurrent malignancy or malignancy within 2 years prior to C1D1",
                        "criterion": "malignancy",
                        "requirement": {
                            "requirement_type": "time since diagnosis",
                            "expected_value": {
                                "operator": "<=",
                                "value": 2,
                                "unit": "years"
                            }
                        }
                    },
                    {
                        "exact_snippets": "Concurrent malignancy or malignancy within 2 years prior to C1D1",
                        "criterion": "malignancy",
                        "requirement": {
                            "requirement_type": "concurrent",
                            "expected_value": false
                        }
                    },
                    {
                        "exact_snippets": "with the exception of adequately treated cutaneous basal or squamous cell carcinoma, non-melanomatous skin cancer, curatively resected cervical cancer, or any locally treated malignancy deemed low likelihood for recurrence or metastasis by the investigator",
                        "criterion": "specific malignancy exceptions",
                        "requirement": {
                            "requirement_type": "type",
                            "expected_value": [
                                "adequately treated cutaneous basal cell carcinoma",
                                "adequately treated cutaneous squamous cell carcinoma",
                                "non-melanomatous skin cancer",
                                "curatively resected cervical cancer",
                                "any locally treated malignancy deemed low likelihood for recurrence or metastasis by the investigator"
                            ]
                        }
                    },
                    {
                        "exact_snippets": "with the exception of adequately treated cutaneous basal or squamous cell carcinoma, non-melanomatous skin cancer, curatively resected cervical cancer, or any locally treated malignancy deemed low likelihood for recurrence or metastasis by the investigator",
                        "criterion": "specific malignancy exceptions",
                        "requirement": {
                            "requirement_type": "exclusion from main malignancy criterion",
                            "expected_value": true
                        }
                    }
                ]
            },
            "logical_structure": {
                "exact_snippets": "failed",
                "criterion": "failed",
                "requirement": {
                    "requirement_type": "failed",
                    "expected_value": "failed"
                }
            }
        },
        {
            "identified_line": {
                "line": "* Left Ventricular Ejection Fraction (LVEF) <50% as determined by Multiple Gated acquisition (MUGA) scan or echocardiogram (ECHO) at screening",
                "criterions": [
                    {
                        "exact_snippets": "Left Ventricular Ejection Fraction (LVEF) <50% ... as determined by Multiple Gated acquisition (MUGA) scan or echocardiogram (ECHO) at screening",
                        "criterion": "Left Ventricular Ejection Fraction (LVEF)",
                        "requirement": {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<",
                                "value": 50,
                                "unit": "%"
                            }
                        }
                    },
                    {
                        "exact_snippets": "Left Ventricular Ejection Fraction (LVEF) <50% ... as determined by Multiple Gated acquisition (MUGA) scan or echocardiogram (ECHO) at screening",
                        "criterion": "Left Ventricular Ejection Fraction (LVEF)",
                        "requirement": {
                            "requirement_type": "assessment_method",
                            "expected_value": [
                                "Multiple Gated acquisition (MUGA) scan",
                                "echocardiogram (ECHO)"
                            ]
                        }
                    },
                    {
                        "exact_snippets": "Left Ventricular Ejection Fraction (LVEF) <50% ... as determined by Multiple Gated acquisition (MUGA) scan or echocardiogram (ECHO) at screening",
                        "criterion": "Left Ventricular Ejection Fraction (LVEF)",
                        "requirement": {
                            "requirement_type": "timing",
                            "expected_value": "at screening"
                        }
                    }
                ]
            },
            "logical_structure": {
                "exact_snippets": "failed",
                "criterion": "failed",
                "requirement": {
                    "requirement_type": "failed",
                    "expected_value": "failed"
                }
            }
        },
        {
            "identified_line": {
                "line": "* Concomitant use of medication(s) with a known risk to prolong the QT interval and/or known to cause Torsades de Pointe that cannot be discontinued (within 5 half-lives or 7 days prior to starting study drug) or replaced by safe alternative medication",
                "criterions": [
                    {
                        "exact_snippets": "Concomitant use of medication(s) with a known risk to prolong the QT interval",
                        "criterion": "concomitant medication with risk to prolong QT interval",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": false
                        }
                    },
                    {
                        "exact_snippets": "medication(s) ... known to cause Torsades de Pointe",
                        "criterion": "concomitant medication with risk to cause Torsades de Pointe",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": false
                        }
                    },
                    {
                        "exact_snippets": "cannot be discontinued (within 5 half-lives or 7 days prior to starting study drug) or replaced by safe alternative medication",
                        "criterion": "ability to discontinue or replace risky medication",
                        "requirement": {
                            "requirement_type": "discontinuation or replacement",
                            "expected_value": true
                        }
                    }
                ]
            },
            "logical_structure": {
                "or_criteria": [
                    {
                        "and_criteria": [
                            {
                                "exact_snippets": "Concomitant use of medication(s) with a known risk to prolong the QT interval",
                                "criterion": "concomitant medication with risk to prolong QT interval",
                                "requirement": {
                                    "requirement_type": "presence",
                                    "expected_value": true
                                }
                            },
                            {
                                "exact_snippets": "cannot be discontinued (within 5 half-lives or 7 days prior to starting study drug) or replaced by safe alternative medication",
                                "criterion": "ability to discontinue or replace risky medication",
                                "requirement": {
                                    "requirement_type": "discontinuation or replacement",
                                    "expected_value": false
                                }
                            }
                        ]
                    },
                    {
                        "and_criteria": [
                            {
                                "exact_snippets": "medication(s) ... known to cause Torsades de Pointe",
                                "criterion": "concomitant medication with risk to cause Torsades de Pointe",
                                "requirement": {
                                    "requirement_type": "presence",
                                    "expected_value": true
                                }
                            },
                            {
                                "exact_snippets": "cannot be discontinued (within 5 half-lives or 7 days prior to starting study drug) or replaced by safe alternative medication",
                                "criterion": "ability to discontinue or replace risky medication",
                                "requirement": {
                                    "requirement_type": "discontinuation or replacement",
                                    "expected_value": false
                                }
                            }
                        ]
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "* Prior anti-tumor therapy within 2 weeks of C1D1 (defined as, but not limited to, anti-cancer agents (cytotoxic chemotherapy, immunotherapy, and biologic therapy), radiotherapy, and investigational agents), the \"washout period.\"",
                "criterions": [
                    {
                        "exact_snippets": "Prior anti-tumor therapy within 2 weeks of C1D1 (defined as, but not limited to, anti-cancer agents (cytotoxic chemotherapy, immunotherapy, and biologic therapy), radiotherapy, and investigational agents), the \"washout period.\"",
                        "criterion": "prior anti-tumor therapy",
                        "requirement": {
                            "requirement_type": "time since last therapy",
                            "expected_value": {
                                "operator": ">=",
                                "value": 2,
                                "unit": "weeks"
                            }
                        }
                    },
                    {
                        "exact_snippets": "Prior anti-tumor therapy within 2 weeks of C1D1 (defined as, but not limited to, anti-cancer agents (cytotoxic chemotherapy, immunotherapy, and biologic therapy), radiotherapy, and investigational agents), the \"washout period.\"",
                        "criterion": "prior anti-tumor therapy",
                        "requirement": {
                            "requirement_type": "therapy types",
                            "expected_value": [
                                "anti-cancer agents",
                                "cytotoxic chemotherapy",
                                "immunotherapy",
                                "biologic therapy",
                                "radiotherapy",
                                "investigational agents"
                            ]
                        }
                    }
                ]
            },
            "logical_structure": {
                "exact_snippets": "failed",
                "criterion": "failed",
                "requirement": {
                    "requirement_type": "failed",
                    "expected_value": "failed"
                }
            }
        },
        {
            "identified_line": {
                "line": "* Patient must not have a condition requiring systemic treatment with either corticosteroids or other immunosuppressive medications within 14 days of randomization. Inhaled or topical steroids, and adrenal replacement steroid doses ≤10 mg daily prednisone equivalents are permitted in the absence of active autoimmune disease.",
                "criterions": [
                    {
                        "exact_snippets": "must not have a condition requiring systemic treatment with either corticosteroids or other immunosuppressive medications within 14 days of randomization",
                        "criterion": "condition requiring systemic corticosteroids or other immunosuppressive medications",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": false
                        }
                    },
                    {
                        "exact_snippets": "must not have a condition requiring systemic treatment with either corticosteroids or other immunosuppressive medications within 14 days of randomization",
                        "criterion": "condition requiring systemic corticosteroids or other immunosuppressive medications",
                        "requirement": {
                            "requirement_type": "treatment_timing",
                            "expected_value": {
                                "operator": "<=",
                                "value": 14,
                                "unit": "days before randomization"
                            }
                        }
                    },
                    {
                        "exact_snippets": "Inhaled or topical steroids, and adrenal replacement steroid doses ≤10 mg daily prednisone equivalents are permitted",
                        "criterion": "use of inhaled or topical steroids, and adrenal replacement steroid doses",
                        "requirement": {
                            "requirement_type": "permitted",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "Inhaled or topical steroids, and adrenal replacement steroid doses ≤10 mg daily prednisone equivalents are permitted",
                        "criterion": "use of inhaled or topical steroids, and adrenal replacement steroid doses",
                        "requirement": {
                            "requirement_type": "dose",
                            "expected_value": {
                                "operator": "<=",
                                "value": 10,
                                "unit": "mg daily prednisone equivalents"
                            }
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "and_criteria": [
                            {
                                "exact_snippets": "must not have a condition requiring systemic treatment with either corticosteroids or other immunosuppressive medications within 14 days of randomization",
                                "criterion": "condition requiring systemic corticosteroids or other immunosuppressive medications",
                                "requirement": {
                                    "requirement_type": "presence",
                                    "expected_value": true
                                }
                            },
                            {
                                "exact_snippets": "must not have a condition requiring systemic treatment with either corticosteroids or other immunosuppressive medications within 14 days of randomization",
                                "criterion": "condition requiring systemic corticosteroids or other immunosuppressive medications",
                                "requirement": {
                                    "requirement_type": "treatment_timing",
                                    "expected_value": {
                                        "operator": "<=",
                                        "value": 14,
                                        "unit": "days before randomization"
                                    }
                                }
                            }
                        ]
                    },
                    {
                        "not_criteria": {
                            "and_criteria": [
                                {
                                    "exact_snippets": "Inhaled or topical steroids, and adrenal replacement steroid doses ≤10 mg daily prednisone equivalents are permitted",
                                    "criterion": "use of inhaled or topical steroids, and adrenal replacement steroid doses",
                                    "requirement": {
                                        "requirement_type": "permitted",
                                        "expected_value": true
                                    }
                                },
                                {
                                    "exact_snippets": "Inhaled or topical steroids, and adrenal replacement steroid doses ≤10 mg daily prednisone equivalents are permitted",
                                    "criterion": "use of inhaled or topical steroids, and adrenal replacement steroid doses",
                                    "requirement": {
                                        "requirement_type": "dose",
                                        "expected_value": {
                                            "operator": "<=",
                                            "value": 10,
                                            "unit": "mg daily prednisone equivalents"
                                        }
                                    }
                                }
                            ]
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "* Patient has any other concurrent severe and/or uncontrolled medical condition that would, in the investigator's judgment, cause unacceptable safety risks, contraindicate patient participation in the clinical study or compromise compliance with the protocol (e.g. chronic symptomatic pancreatitis, chronic active hepatitis, active untreated or uncontrolled fungal, bacterial, or viral infection).",
                "criterions": [
                    {
                        "exact_snippets": "any other concurrent severe and/or uncontrolled medical condition",
                        "criterion": "concurrent medical condition",
                        "requirement": {
                            "requirement_type": "severity",
                            "expected_value": "severe"
                        }
                    },
                    {
                        "exact_snippets": "any other concurrent severe and/or uncontrolled medical condition",
                        "criterion": "concurrent medical condition",
                        "requirement": {
                            "requirement_type": "control_status",
                            "expected_value": "uncontrolled"
                        }
                    },
                    {
                        "exact_snippets": "chronic symptomatic pancreatitis",
                        "criterion": "chronic symptomatic pancreatitis",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "chronic active hepatitis",
                        "criterion": "chronic active hepatitis",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "active untreated or uncontrolled fungal, bacterial, or viral infection",
                        "criterion": "active infection",
                        "requirement": {
                            "requirement_type": "treatment_status",
                            "expected_value": "untreated"
                        }
                    },
                    {
                        "exact_snippets": "active untreated or uncontrolled fungal, bacterial, or viral infection",
                        "criterion": "active infection",
                        "requirement": {
                            "requirement_type": "control_status",
                            "expected_value": "uncontrolled"
                        }
                    },
                    {
                        "exact_snippets": "active untreated or uncontrolled fungal, bacterial, or viral infection",
                        "criterion": "active infection",
                        "requirement": {
                            "requirement_type": "infection_type",
                            "expected_value": [
                                "fungal",
                                "bacterial",
                                "viral"
                            ]
                        }
                    }
                ]
            },
            "logical_structure": {
                "exact_snippets": "failed",
                "criterion": "failed",
                "requirement": {
                    "requirement_type": "failed",
                    "expected_value": "failed"
                }
            }
        }
    ],
    "failed_miscellaneous": []
}